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Regulation of Myc oncoprotein function by E3 ubiquitin ligases. 
Abstract 
The Myc oncoprotein/transcription factor plays an important role in controlling 
cell proliferation, and is deregulated in many human cancers. Myc is a short-lived 
protein that is turned over via the ubiquitin-proteasome pathway. The major aim of 
this thesis was to identify E3 ubiquitin ligases that regulate Myc turnover and/or 
function. Further we aimed to understand the mechanisms behind IFN--induced 
inactivation of Myc. 
Through this work we identified the first E3 ligase, SCF
Skp2, interacting with Myc 
and promoting its ubiquitylation and proteasomal turnover. Surprisingly, Skp2 
promotes Myc-induced S-phase entry and is required for transcriptional activation 
by Myc. We show that Myc recruits Skp2 and the proteasome to target promoters 
and that the proteasome subunit Sug1 is required for Myc transactivation, 
suggesting that both Skp2 and Sug1 act as coactivators for Myc-induced 
transcription.  
We further found an interaction between Myc and the tumour suppressor/E3 
ligase von Hippel Lindau (VHL) that targets hypoxia-inducible factor (HIF) for 
degradation. Unlike HIF, Myc binds VHL also during hypoxia through a distinct 
binding site. VHL is shown to play a role in ubiquitylation of Myc, but surprisingly 
not in degradation, thus displaying a new non-proteasomal VHL function. Further, 
VHL interacts with a subset of Myc target promoters and is possibly involved in 
regulation of certain Myc target genes. 
We also present results showing that Cyclin E/Cdk2 regulates the stability of 
Myc by phosphorylating Ser-62 and functions as a Myc cofactor, increasing Myc 
transactivation and stability. We further show that this phosphorylation is inhibited 
by the growth inhibitory cytokine IFN- via upregulation of the Cdk inhibitor 
p27, resulting in increased Myc turnover via the ubiquitin/proteasome pathway. 
Taken together, this thesis presents three examples of regulation of Myc 
ubiquitylation with different consequences for Myc function and stability. These 
findings emphasise the importance of Myc regulation by E3 ligases at different 
biological levels and could potentially be of importance for the development of 
novel cancer therapeutics. 
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1  Background 
1.1  Development of cancer 
For a normal cell to transform into a cancer cell, genes that regulate cell 
growth and differentiation must be altered (Croce, 2008). Genetic changes 
can occur at many levels, from point mutations changing one nucleotide to 
gain or loss of entire chromosomes. The altered gene expression can also be 
due to epigenetic changes for instance in DNA methylation. Typically, 
cancers are caused by a series of mutations where each mutation alters the 
behavior of the cell to some extent. The majority of human cancers have an 
enhanced mutation rate, the cells are genetically unstable. This instability can 
be due to defects in either DNA replication repair or the cells ability to 
repair local DNA damage. Two broad classes of genes are targets for 
cancerous mutations: proto-oncogenes and tumour suppressor genes. 
Mutations in proto-oncogenes that cause an overactive protein are “gain of 
function” mutations and their mutant forms are called oncogenes. Mutations 
are usually dominant and mutation in one allele is sufficient to become an 
oncogene. Mutations that inactivate a tumour suppressor gene, a “lose of 
function” mutation, subsequently drive the cell towards cancer. Mutations 
in tumor suppressors are typically recessive and both alleles usually need to 
be affected for the “lose of function” phenotype. 
Hanahan and Weinberg suggest that in most or perhaps all tumors the 
neoplastic cells need to aquire six types of alterations that collectively dictate 
malignant growth (Hanahan & Weinberg, 2000). The alterations are: self-
sufficiency in growth signals, insensitivity to growth-inhibtory signals, 
evasion of programmed cell death, limitless replicative potential, sustained 
angiogenesis and tissue invasion and metastasis. For proliferation, normal 
cells need mitogenic growth signals, which are transmitted into the cells via   12 
transmembrane receptors. These growth signals can be diffusible growth 
factors, extracellular matrix components or cell to cell adhesion molecules 
and are mimicked in some way by oncogenes in cancer (Hanahan & 
Weinberg, 2000). To overcome the impact of antigrowth signals, which 
drives the cell into the resting G0-phase or differentiation, a cancer cell 
usually has disruptions in the Rb-pathway (described in chapter 1.2). One 
example of an antigrowth signal is TGFβ that acts in a number of ways to 
prevent phosphorylation of Rb, for a review see (Massague et al., 2000). 
Apoptosis is a mechanism that can be triggered by an activated oncogene 
and has to be overcome in a cancerous cell. Loss of proapoptotic regulators 
is one strategy to become resistant to programmed cell death. Mutations in 
the p53 tumour suppressor, is seen in more than 50% of human cancers and 
results in an impaired DNA damage sensor protein that can induce the 
apoptotic effector cascade (Harris, 1996). Cancer cells also have to overcome 
the cell-autonomous programme that limits their multiplication by 
shortenting of telomeres. Most cancer cells abrogate this by upregulation of 
the telomerase enzyme which adds hexanucleotide repeats onto the ends of 
telomeric DNA (Bryan & Cech, 1999; Shay & Bacchetti, 1997). The fifth 
barrier to overcome in cancer is to maintain oxygen and nutrient supply to 
the tumor, which means there must be a capillary blood vessel within 
100µm from all cells (Tonini et al., 2003). The most important molecule 
that controls blood-vessel morphogenesis is vascular endothelial 
growthfactor A (VEGF A) that is required for chemotaxis and differentiation 
of endothelial precursor cells, endothelial proliferation as well as assembly of 
endothelial cells into vascular structures and angiogenic remodeling (Adams 
& Alitalo, 2007). In hypoxic cells the hypoxia inducible factor  activates 
proangiogenic factors (Liotta & Stetler-Stevenson, 1991). The sixth obstacle 
to overwin is the limited space for tumor growth, which the cancer cells 
solve with invasion of other tissues and metastasis. Like the formation of the 
primary tumor, the success of invation and metastasis depends upon all the 
other five aquired capabilities (Hanahan & Weinberg, 2000).  
1.2  General features of the mammalian cell cycle 
The cell cycle is an essential mechanism by which all living organisms 
reproduce. To produce two identical daughter cells, the cell must replicate 
its DNA into two perfect copies and then segregate the copies into two 
genetically identical daughter cells.  
The cell cycle consists of four distinct phases: G1 phase, S phase, G2 phase 
(collectively known as interphase) and M phase. DNA duplication occurs in   13 
S-phase, which takes approximately 10-12 hours in a mammal. When the 
chromosomes have been duplicated, cells can enter the M-phase where 
chromosome segregation, mitosis, and cytoplasmic division, cytokinesis, take 
place. Mitosis and cytokinesis takes typically one hour in a human cell. 
Mitosis can be divided further into five phases: prophase, prometaphase, 
metaphase, anaphase and telophase. Between the M- and S phases there are 
two Gap phases G1 and G2. G1 appears after M-phase and allows the cell to 
grow and the environment to become favourable before the cell commits 
itself to enter the S-phase. Therefore the length of G1 can vary depending 
on external conditions and extracellular signals. If extracellular conditions are 
unfavourable, cells can delay their process through G1 and even enter a 
resting state named G0. The second gap-phase G2 takes place between S- 
and M-phase. There are several checkpoints during the cell cycle. In late 
G1, there is a restrictionpoint checking that the cell is ready for DNA 
replication. After passing this point, cells are committed to DNA replication, 
even if extracellular signals that stimulate growth and cell division are 
withdrawn. Another restriction point is in the end of G2 when the cells are 
about to enter M-phase in order to check that all DNA is replicated and that 
the environment is favourable. In late M-phase, there is an additional 
checkpoint to check that all chromosomes are attached to the mitotic 
spindle so the cells can proceed to anaphase and cytokinesis. 
In order to maintain correct cell division, the eukaryotic cell cycle is 
tightly regulated. Temporal activation of different cyclin dependent kinase 
(Cdk)/cyclin complexes regulates the phases of the cell cycle and drives it 
forward. Whilst the level of Cdks remains relatively stable during the cell 
cycle, the level of cyclins generally oscillates. Cyclins are synthesized, bind 
and activate the Cdk and are then destroyed (Arellano & Moreno, 1997). 
Cdks are serine/threonine kinases and associate with the cyclin box, a 100 
amino acids conserved sequence in all cyclins. The general Cdk activity is 
very low in early G1, progresses in mid-late G1, S and peak in mitosis for a 
subsequent rapid decay (Morgan, 1997). There are nine Cdks (Cdk1-9) and 
at least 16 cyclins, which are linked to different phases of the cell cycle 
(Johnson & Walker, 1999). In G1, there are three D-type cyclins (D1, D2 
and D3) and two E-type cyclins (E1 and E2). The cyclin Ds interact with 
Cdk4 and Cdk6 whereas cyclin E bind Cdk2, but can also interact and 
activate Cdk1 (Aleem et al., 2005; Morgan, 1997). Various combinations of 
D-type cyclins are expressed in different cell types, whereas cyclin E–Cdk2 
complexes are expressed ubiquitously. Both the D- and E-type cyclins, and 
their associated kinases, had been thought to be necessary and "rate-limiting" 
for entry into and progression through the G1 phase of the cell cycle (Sherr   14 
& Roberts, 2004). The cyclin D-dependent kinases are activated by 
mitogenic signaling and phosphorylate Rb family members (Rb, p107, and 
p130), thus releasing E2F that activates
 a battery of genes whose products are 
required for DNA metabolism
 and replication (Trimarchi & Lees, 2002). 
Additionally, cyclin D–Cdk complexes promote G1 progression by 
sequestering proteins of the Cip/Kip family,
 including p27
Kip1 and p21
Cip1, 
both inhibitors of Cdk2 (Polyak et al., 1994; Reynisdottir et al., 1995). 
 
 
Figure 1. A simplified illustration of the cyclin/Cdks and their inhibitors within the 
mammalian cell cycle. 
 
The activity of cyclin E–Cdk2 is maximal at the G1- to S-phase transition 
and their downstream targets include a subset of the G1 inhibitors that are 
also targeted by the D-type cyclins: Rb and p27
Kip1. Cyclin E–Cdk2 does not 
sequester p27
Kip1, but
 rather phosphorylates it on a single threonine residue, 
T187, (Sheaff et al., 1997; Vlach et al., 1997) providing a recognition
 motif 
for SCF
Skp2, an E3 ligase that targets phosphorylated
 p27
Kip1 for ubiquitination 
and subsequent degradation (Elledge & Harper, 1998). SCF
Skp2 will be 
discussed further in paper I and II. In early S-phase, there is an abrupt decay 
of cyclin E–Cdk2 activity that results from cyclin E degradation. A prior 
phosphorylation by
  both glycogen synthase kinase 3 beta (GSK-3β) and 
Cdk2 itself is required to target cyclin E for
 ubiquitination by the SCF
Fbw7 E3 
ligase, leading to proteasomal
 degradation (Clurman et al., 1996; Welcker et 
al., 2003; Won & Reed, 1996). In late G1, another cyclin that pairs with   15 
Cdk2, namely cyclin A, makes entrance. Cyclin A-Cdk2 activity steadily 
increases as cells begin to replicate their DNA, and do not decline until 
cyclin A is degraded in early mitosis. Cyclin A–Cdk2 is thought to 
phosphorylate substrates that start DNA replication from preassembled 
replication initiation complexes (Krude et al., 1997) and in the same manner 
as cyclin E, cyclin A2 is induced by E2F. During G2 and M-phase cyclin A 
and and Cyclin B together with Cdk1 control the cell cycle process 
(Arellano & Moreno, 1997). However, during the last few years knockout 
studies in mice have shed new light over how cdks regulate the cell cycle. 
Mouse embryos lacking all interphase Cdks (Cdk2, Cdk3, Cdk4 and Cdk6) 
undergo organogenesis and develop to midgestation. In these embryos, 
Cdk1 binds to all cyclins, resulting in the phosphorylation of the 
retinoblastoma protein pRb and the expression of genes that are regulated 
by E2F transcription factors, suggesting that Cdk1 compensates for loss of 
any of Cdk2, Cdk3, Cdk4 and Cdk6 (Santamaria et al., 2007). 
There are two major families of Cdk inhibitors (CKIs): the Ink4 family 
p16
INK4a, p15
INK4b, p18
INK4c and p19
INK4d that inhibit Cdk4/6 as well as the 
Cip/Kip family: p27
Kip1, p21
Cip1and p57
Kip2 that inhibit a broader spectrum of 
cyclin-cdk complexes (for a review see (Vermeulen et al., 2003; Vidal & 
Koff, 2000)). The Cip/Kip family proteins have also shown to be involved 
in other activities such as regulation of actin filaments, for reviews see 
(Denicourt & Dowdy, 2004; Sicinski et al., 2007). Additionally, Wee-1 
catalyzes an inhibitory tyrosine phosphorylation of cyclin B/Cdk1 and 
operates at the G2 to M-phase checkpoint. Cdc25 is a phosphatase that 
removes the inhibitory phosphate added by Wee-1, rendering the complex 
active (for a review see (Pines, 1999)). 
1.3  Brief Overview of Transcriptional Regulation 
Eukaryotic transcription is an extremely complex and tightly regulated 
process. The components involved in regulation of gene transcription are: 
DNA-binding transcriptional activators and repressors and their cofactors, 
general transcription factors, RNA polymerase I-III complexes and 
chromatin-structure regulatory factors. RNA polymerase I transcribe rRNA, 
RNA polymerase II (PolII) transcribe protein coding genes whereas RNA 
polymerase III facilitate transcription of 5S RNA/tRNA. Only PolII 
dependent transcription will be discussed here.   16 
1.3.1  Initiation of transcription 
Initiation of transcription requires a great mass of proteins including the 
general transcription factors TFIIB, TFIID, TFIIE, TFIIF, TFIIH and 
TFIIA. (For a review see (Reese, 2003)). The first step is recognition of the 
target promoter by TATA-binding protein (TBP) and the TBP associated 
factors (TAFs), which all are parts of TFIID. TAFs recognize the promoter 
sequences Inr (TAF2) and DPE (TAF6). Upon binding DNA, TFIID makes 
a bending of the DNA-helix, creating a platform for the remaining general 
transcription factors. TFIIB subsequently binds in order to stabilize the 
interaction between the promoter and TFIID. TFIIB then recruites the 
PolII-TFIIF complex and thereafter the two final basal transcription factors: 
TFIIE and TFIIH bind in into this preinitiation complex (PIC). TFIIH 
possess helicase activity and unwinds DNA at the promoter in an ATP-
dependent manner (for a review see (Coin & Egly, 1998; Dvir et al., 2001)). 
In order to induce promoter release and transcriptional elongation, 
phosphorylation of the C-terminal tail of polII occurs to release polII from 
the PIC. PolII is suggested to be phosphorylated by positive transcriptional 
elongation factor b (PTEFb) which is a complex consisting of Cdk9 and 
CyclinT1, T2 or K (for a review see (Conaway et al., 2000)). TFIIH is also 
s u g g e s t e d  t o  b e  i n v o l v e d  i n  p h o s p horylation of the CTD tail of PolII 
(Cowling & Cole, 2007). Also other factors are involved in promoter 
release. One example is elongin that consists of elongin A, B and C and 
function by suppressing pausing of PolII at the promoter (Aso et al., 1995). 
1.3.2  Coregulators 
Besides the general transcription factors, a gene needs specialized 
coregulators, coactivators and cosupressors, in order to be transcribed. The 
coactivators can roughly be divided into three classes (Spiegelman & 
Heinrich, 2004). The first group consists of proteins that modify histones 
(discussed below), examples are Gcn5, PCAF, p300 and CBP (CREB-
binding protein). The second group comprises proteins that bind to 
transcription factors, recruite RNA polymerase II and interact with the basal 
transcription machinery, such as the mediator complex. The mediator is a 
large protein complex containing up to 30 subunits and is conserved from 
yeast to human. The mediator brings activators and PolII together, 
functioning as a bridge by transduction of regulatory signals (Kornberg, 
2005; Malik & Roeder, 2005). Noteworthy, the mediator is not only 
activating transcription, but also plays a role in repression of transcription 
(Kornberg, 2007). The third group of co-regulators is ATP-dependent 
DNA-unwinding chromatin remodelling complexes such as members of the   17 
yeast Swi/Snf family, with the mammalian homologs BRG1 or BRM 
(Featherstone, 2002; Spiegelman & Heinrich, 2004), which will be discussed 
below. 
Corepressors have a densing effect on chromatin structure and they 
generally function by either recruiting histone deacetyl transferases (HDACs) 
or by physically interfering with activator complexes or PIC. Examples of 
co-repressors are SMRT (silencing mediator of retinoic and thyroid 
hormone receptor) and N-CoR (nuclear hormone receptor co-repressor) 
(Wong & Privalsky, 1998), for a review see (Privalsky, 2004). 
 
 
 
Figure 2. Some of the components involved in transcriptional regulation 
1.3.3  Histone modifications and chromatin remodeling 
The eukaryotic DNA is neatly wrapped around histone particles and packed 
into nucleosomes. One histone octamer is build up by two copies of each of 
the histone subunits H2A, H2B, H3 and H4. DNA is wrapped two 
superhelical or 1.65 turns around each histone, making 14 contact points 
between the histone and DNA which results in a very stable protein-DNA 
complex. Histone H1 is not a part of the histone octamer, but it functions as 
a linker twisting and folding the nucleosome particles into a very tightly 
packed chromatin structure. For transcription to occur, the dense 
heterochromatin must be transformed to a more lose euchromatin to enable 
the transcriptional machinery to bind DNA. Two mechanisms have evolved 
to modify chromatin structure: modifications of histones and nucleosome 
remodeling (Spiegelman & Heinrich, 2004).   18 
Histones are known to be targeted by several post-translational 
modifications including phosphorylation, acetylation, ubiquitylation and 
methylation (Strahl & Allis, 2000). Acetylation of histones has proved to be 
associated with less tight chromatin and activation of transcription whereas 
deacetylation of histones is connected to silent genes. Histone acetyl 
transferases (HATs) acetylate lysine residues in the N-terminal tail of 
histones. Two superfamilies of HATs have been characterized: the GNAT 
(Gcn-related N acetyltransferase) family and the MYST (MOZ, Ybf 2/Sas3, 
Sas2 and Tip60) family and additionally, CBP/p300 that not fits into any of 
these families (Bazan, 2008; Hodawadekar & Marmorstein, 2007). Among 
the Gcn-related acetyltransferases some examples are Gcn5 and PCAF 
(p300/CBP-binding protein-associated factor). Gcn5 prefers acetylation of 
H3, but also acetylate H4, and is a component of the SAGA complex 
(SPT/ADA/GCN5/Acetyltansferase) which consists of about 20 proteins, 
most of them conserved from mammals to yeast. CBP/p300 acetylates all 
four core histones and PCAF interacts with H3 and H4, but not H2A and 
H2B. Both PCAF and CBP/p300 acetylate other proteins than histones, 
such as p53. One example from the MYST superfamily is Tip60 that 
particularly acetylates histone H2A/H4, for a review see (Sapountzi et al., 
2006). 
Histone deacetylases (HDACs) remove acetyl residues from the N-
terminal tail of histones and thereby create a more dense chromatin structure 
that leads to repression of transcription. Mammalian HDACs are classified 
into HDAC I-III based upon sequence similarity to the yeast HDACs 
(Rpd3, Had1 and Sir2). HDAC class I (HDAC1, 2, 3 and 8) and class II 
(HDAC4, 5, 6, 7, 9 and 10) are the best characterized HDACs. HDACs are 
recruited to transcriptional units by co-repressors such as Sin3 and 
NCoR/SMRT (Alland et al., 1997).  
Another way of regulating the accessibility of DNA is by ATP-dependent 
chromatin remodelling. ATP-dependent complexes such as Swi/Snf, RSC, 
Mi-2/NuRD alter chromatin structure by unwinding DNA and changing 
the location or conformation of the nucleosome without covalent 
modifications. The Swi/Snf complex family was first found in yeast and its 
most known member is Swi2/Snf2 with the mammalian homolog 
hBRM/hSNF2 and hBRG1/hSNF2b. Swi/Snf complexes can function as 
either activators or repressors, for a review see (Martens & Winston, 2003). 
Some transcription factors have been reported to interact with Swi/Snf 
complexes, including the Myc oncoprotein and the C/EBP transcriptional 
activator (Naar et al., 2001).   19 
1.4  Ubiquitin regulates biological processes 
Before the ubiquitin-proteasome system was discovered, the lysosome was 
believed to degrade both exogenous and endogenous proteins. However, 
this rather unspecific lysosomal degradation, in the case of intracellular 
proteins, proved to have a much more sophisticated “cousin”, the ubiquitin 
proteasome system, which degrades endogenous proteins in a specific 
manner (Ciechanover et al., 1980; Hershko et al., 1980). The discovery of 
the ubiquitin-proteasome system resulted also in the realization that 
regulated protein degradation is involved in a wide range of cellular 
processes such as the cell cycle and cell division, apoptosis, transcription, 
antigen presentation, signal transduction, receptor mediated endocytosis, 
protein quality control and metabolic pathways (Ciechanover, 2005). 
Altogether, it is estimated that several percent of the human genome is 
devoted to the ubiquitin pathway taking into account both proteolytic and 
non-proteolytic functions (Semple, 2003). 
1.4.1  Ubiquitylation-a multistep process with different fates 
Ubiquitin is a 76-amino acid polypeptide (Goldstein, 1974; Goldstein, 1975; 
Schlesinger et al., 1975) that is highly conserved and expressed in all 
eukaryotes. Attaching a chain of ubiquitin molecules on a target substrate is 
a process termed ubiquitylation. Ubiquitylation is a multistep reaction 
involving at least three types of enzymes E1, E2 and E3 (Hershko et al., 
1983). At first, E1, ubiquitin activating protein, forms a thiol-ester bond 
with the C-terminal glycine on the ubiquitin protein, a process that requires 
ATP. Secondly, E2, ubiquitin conjugating enzyme, accepts ubiquitin from 
the E1 by a transesterification reaction. E3 then binds ubiquitin charged E2 
as well as the target protein and facilitates formation of an isopeptide bond 
between the carboxyl-terminal glycine of ubiquitin and the ε-amino group 
of a lysine residue on the target substrate. When one ubiquitin molecule has 
been attached to the target protein, further ubiquitins can be attached to a 
lysine residue on the surface of the first ubiquitin molecule, in order to build 
a poly-ubiquitin chain, or the target protein can remain mono-
ubiquitylated. (For reviews see (Fang & Weissman, 2004; Pickart & Eddins, 
2004; Weissman, 2001)). Ubiquitin has seven internal lysine residues (K6, 
K11, K27, K29, K33, K48 and K63) and all seven residues have been found 
to participate in ubiquitin-ubiquitin interactions, which gives a potential for 
enormous complexity (Peng et al., 2003). However, ubiquitins are generally 
linked through K48, K63, or in some cases K29 (Pickart, 2001; Weissman, 
2001). The K48 linked polyubiquitin chains are recognized by the 26S 
proteasome for subsequent degradation, which will be described in more   20 
detail below. K63 linked ubiquitin chains label target proteins for a range of 
non-proteasomal faiths. K63 linkage has been implicated in DNA-repair 
(Spence et al., 1995), ribosome modification (Spence et al., 2000), activation 
of IB kinase (Deng et al., 2000), endocytosis (for a review see (Bonifacino 
& Weissman, 1998; Rotin et al., 2000)) and transcriptional activation 
(Adhikary et al., 2005). K29-linked ubiquitin chains have been suggested to 
participate in lysosomal degradation of proteins (Chastagner et al., 2006) and 
K29/K33-linked mixed ubiquitin chains have recently been implicated in 
regulation of AMP-activated protein kinase (AMPK)-related kinases (Al-
Hakim et al., 2008). 
The 26S Proteasome 
The 26S proteasome recognizes polyubiquitylated proteins and degrades 
them to small peptides. A minimum of four ubiquitin molecules linked to 
each other are required for recognition by the proteasome (Thrower et al., 
2000). The 26S proteasome is composed of two multisubunit complexes; a 
core protease, named the 20S proteasome and a regulatory element, termed 
the 19S regulatory particle. The 20S proteasome has a barrel-formed 
structure with four ring-formations consisting of two copies of 14 different 
proteins (α1-7 and β1-7) arranged as α1-7,  β1-7,  β1-7,  α1-7. The 
proteolytic lumen of the proteasome is build up of the β1,  β2 and β7 
subunits, which forms a catalytic active site in the middle of the cylinder. 
The regulatory particle is a 20-subunit complex which binds to one or both 
sides of the 20S cylinder, positioning itself as a gatekeeper to the catalytic 
core. The 19S regulatory particle is composed of two multisubunit 
complexes; the 19S base or APIS, containing six ATPases (Rpt1-6) and 
three non-ATPase subunits (Rpn1, 2 and 13) and the lid consisting of the 
remaining Rpn subunits (Rpn3-12). The non-ATPases Rpn1, 2 and 13 
bind to the ATPase ring and mediate the interaction to the lid. The function 
of most subunits of the lid is presently unknown, but some lid-subunits 
posses deubiquitinating (DUB) activity (see below) and one subunit 
(Rpn10/S5a) has an ubiquitin interaction motif, which binds polyubiquitin 
chains (Elsasser et al., 2004; Verma et al., 2004). Also Rpn13 in the 19S base 
subunit has shown to interact with ubiquitin molecules (Husnjak et al., 
2008). The ATPases in the base subunit unfold the deubiquitylated target 
protein and then promote the opening of the pore and access to the catalytic 
core (Benaroudj et al., 2003). The overall 26S proteasomal protein 
degradation is energy consuming and hydrolyzes ATP with an unknown 
mechanism. It has been suggested that the energy-dependent steps are linked   21 
to substrate unfolding, translocation and deubiquitylation (Baumeister et al., 
1998; Pickart & Cohen, 2004).  
Ubiquitylation is not an irreversible process. Deubiquitinating enzymes 
(DUBs) remove ubiquitin molecules from mono- or polyubiquitylated 
proteins. As mentioned above, one function of DUBs are to be parts of the 
proteasomal lid subunit, where they cleave off and recycle ubiquitin 
molecules from the proteins that are about to get degraded by the 
proteasome (Verma et al., 2002). 
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Figure 3. Components involved in the ubiquitin-proteasome system. (Printed with permission 
from N. von der Lehr.) 
1.4.2  E3 ligases 
There are two E1 activating enzymes, dozens of E2 conjugating enzymes 
and hundreds E3 ubiquitin ligases characterized until date (Li & Ye, 2008). 
Under certain circumstances also an additional enzyme, an E4 ubiquitin 
elongating factor, are required for extension of the ubiquitin chain (Hoppe, 
2005; Koegl et al., 1999).   23 
E3 ubiquitin ligases are classified into three major classes; HECT 
(Homologous to E6-AP Carboxyl Terminus) (Huibregtse et al., 1995; 
Scheffner et al., 1993), RING (Really Interesting New Gene) finger 
(Lovering et al., 1993) and U-box E3 (Aravind & Koonin, 2000; 
Hatakeyama et al., 2001; Koegl et al., 1999). 
HECT 
The first E3 ligase to be identified was the E6-AP (E6-Asociated Protein) 
that mediates ubiquitylation of p53. E6 proteins of the oncogenic human 
papilomavirus (HPV) were discovered to bind p53 and stimulate its 
degradation which is catalysed by E6-AP (Scheffner et al., 1993; Scheffner et 
al., 1990). It was then found that a number of proteins share homology with 
the carboxyl-terminal half of E6-AP and thus these where given the name 
HECT (Homologous to E6-AP Carboxyl Terminus) domain proteins 
(Huibregtse et al., 1995). The HECT domain is approximately 350 amino 
acids long and highly conserved. A cystein that is positioned about 35 amino 
acids upstream of the C-terminus accepts ubiquitin from bound E2s for 
subsequent transfer to the substrate. The amino-terminal part of the HECT 
E3 ligase recognizes the target substrate and regulate subcellular localization 
(Weissman, 2001).  
RING 
The RING finger E3 contains an octet of histidine and cystein residues 
building up a zinc binding domain and is structurally classified as either 
RING-H2 which contains two histidines or RING-HC, which only possess 
one histidine. The majority, but probably not all, of the RING finger 
domain proteins function as E3 ligases (Lorick et al., 1999). The RING 
finger E3 ligases can be divided into several subgroups on the basis of 
structural or molecular similarities. The subclasses are; Cullin-RING, 
APC/C (anaphase promoting complex/cyclosome) and single-polypeptide 
RING-finger (SPRF) E3s. The Cullin-RING E3 is the largest subclass and 
can be further divided into seven subgroups containing the Cullins: 1, 2, 3, 
4a, 4b, 5 and 7 respectively, that together with an E2-binding RING finger 
protein (Rbx1 or Rbx2) form the E3 core. Below I will describe the most 
well-known Cullin-RING E3s: SCF (Skp1-Cullin-F-box protein) and 
CBC (Cul2-elongin B-elongin C) in more detail. 
The SCF complex consists of Rbx1, Skp1, Cul1 and an F-box protein, 
which is the target recognition component of the E3 ligase. The F-box 
protein has an F-box domain that mediates interaction with Skp1 and a 
substrate interaction domain such as WD40 repeats or leucin rich repeats   24 
(LRR), which interacts with the target protein. There are dozens of F-box 
proteins identified, but one of the most studied is the LRR F-box protein 
S-phase associated kinase associated protein 2 (Skp2). The expression of 
Skp2 varies around the cell cycle and is first detected at the G1/S transition, 
then it accumulates during S/G2 transition and finally drops as the cells 
proceed through M-phase (Lisztwan et al., 1998). Skp2 is suggested to 
recognize many substrates involved in cell cycle progression including; p21 
(Bornstein et al., 2003; Yu et al., 1998b), p27 (Carrano et al., 1999; 
Sutterluty et al., 1999; Tsvetkov et al., 1999), p57 (Kamura et al., 2003), 
Cyclin E (Nakayama et al., 2000; Yeh et al., 2001), E2F-1 (Marti et al., 
1999) and CyclinD (Yu et al., 1998b). p27 is the most established target of 
Skp2 and in Skp2
￿/ ￿p27
￿/ ￿ double knock out mice, most of the cellular 
abnormalities apparent in Skp2
￿/ ￿ mice were not evident, suggesting p27 to 
be the primary target of Skp2 (Nakayama et al., 2004). There are several 
evidences implicating that Skp2 is an oncogene (Yamasaki & Pagano, 2004). 
Skp2 expression correlates with tumour malignancy and agressivenessnad is 
associated with poor prognosis in breast carcinomas, colorectal carcinomas, 
oral squamous cell carcinomas, gastric carcinomas, prostate cancers, 
lymphomas and human astrocytic gliomas (Bloom & Pagano, 2003; 
Guardavaccaro & Pagano, 2004). 
The CBC complex comprises Rbx1, Cul2, elongin B, elongin C and 
VHL. The CBC-complex show structural and sequential similarities to the 
SCF complex. Cul1 and Cul2 as well as Skp1 and elongin C share amino 
acid sequence homology. Moreover, the pattern of hydrophobic amino 
acids of the Skp1-binding F-box sequence motif matches that of the VHL 
alpha-domain. The similarities include both residues involved in elongin C 
binding and residues involved the alpha-domain stabilization. However, 
there is little sequential similarity and no cross-reactivity occurs, which 
suggests a loose structural similarity between the F-box sequence motif and 
the VHL alpha-domain (Stebbins et al., 1999). VHL recognizes the hypoxia 
inducible factor α (HIFα) transcription factors; HIF1α, HIF2α and HIF3α 
for oxygen-dependent degradation (Maxwell et al., 1999; Maynard et al., 
2003). Oxygen is needed for hydroxylation of HIF by prolyl-hydroxylases 
which is a pre-requisite for recognition by VHL (Bruick & McKnight, 
2001; Epstein et al., 2001; Semenza, 2001). In hypoxic conditions, HIFα 
accumulates and heterodimerize with HIFβ subunits in order to bind DNA 
and activate transcription of hypoxia induced genes. The features of VHL 
and oxygen sensing will be described in more detail in chapter 1.6. 
The APC/C was identified as an E3 that mediates degradation of cyclin B 
and thereby promotes M-phase exit. The APC/C complex consists of 11   25 
subunits, including APC2 and APC11, which are similar to Cul1 and Rbx1, 
respectively (Yu et al., 1998a). 
The SPRF E3s consist of a single polypeptide containing a RING-finger 
domain. The wide range of SPRF E3 include Cbl, that degrades epidermal 
growth factor and platelet-derived growth factor (Joazeiro et al., 1999), 
Mdm2, that regulate p53 levels in the cell (Honda & Yasuda, 1999), IAPs 
(inhibitor of apoptosis) (Yang et al., 2000) and Parkin (Imai et al., 2001; 
Shimura et al., 2001; Weissman, 2001; Yang et al., 2000). 
U-box and others 
The U-box domain is distantly related to the RING finger domain in 
sequence, but without conserved zinc coordinating residues (Fang & 
Weissman, 2004). UFD2 was the first U-box to be implicated in 
ubiquitylation. UFD2 was first of all believed to be an E4 ubiquitin chain 
elongation factor cooperating with the E3 UFD4 (Koegl et al., 1999). 
However, now UFD2 is known to be a U-box E3 that can mediate 
ubiquitylation independent of other E3s (Aravind & Koonin, 2000; 
Hatakeyama et al., 2001). Several U-box E3s have now been discovered, 
among them the CHIP (Carboxyl-terminus of Hsc70 Interacting Protein) 
E3 ligase, that interacts with the molecular chaperone Hsp90 in order to 
degrade unfolded proteins (Connell et al., 2001; Jiang et al., 2001; Meacham 
et al., 2001). 
The PHD (Plant Homeo-Domain) or LAP (Leukemia-Associated Protein) 
is a RING finger variant, but it possesses a cystein instead of one of the 
histidines and an invariant tryptophane in the zinc binding motif (Capili et 
al., 2001). PHD finger dependent E3 activities has been shown for 
mammalian proteins such as MEKK1 and several herpes virus encoded PHD 
finger proteins have been implicated in ubiquitylation of major 
histocompatibility complex (MHC) class I (Boname & Stevenson, 2001; 
Coscoy et al., 2001; Lu et al., 2002). The PHD finger’s involvement in 
ubiquitylation is not clear and there have been conflicting reports (Scheel & 
Hofmann, 2003).  
1.4.3  Ubiquitin in transcriptional activation 
Ubiquitylation has been implicated not only in degradation, but several non-
proteolytic processes such as receptor internalization (Terrell et al., 1998), 
ribosome function (Spence et al., 2000), nucleotide excision repair (Russell 
et al., 1999) as well as transcriptional activation, which will be discussed 
here. One way that the ubiquitin-proteasome pathway can regulate 
transcription is to degrade transcriptional activators that have fulfilled their   26 
mission. The promoter is thereby cleared for fresh proteins to bind and a 
new round of transcription can take place. Activator turnover has indeed 
been coupled to transcriptional activation in some systems (Muratani & 
Tansey, 2003). One of the first examples of this is shown by Natesan and 
colleagues when they showed an inverse correlation between protein levels 
and potency as activators (Molinari et al., 1999). Further, the transcriptional 
activation domain (TAD) of several transcriptional activators overlaps the 
degradation domain, the degron, (Kodadek et al., 2006; Muratani & Tansey, 
2003). This overlap was first shown for the transcription factor c-Myc 
(Salghetti et al., 1999) and subsequently for other short-lived transcription 
factors with an acidic domain (Salghetti et al., 2000). Moreover, Tansey and 
co-workers showed that the ubiquitin ligase Met30 is essential for both the 
destruction and activity of a VP16 transcription factor implying that 
activator ubiquitylation is coupled to transcription and might be needed for 
active transcription (Salghetti et al., 2001). The growing number of E3 
ligases that also are transcriptional coactivators adds to the idea that 
transcriptional activation and ubiquitylation are connected (Muratani & 
Tansey, 2003).  
Active promoters have also been shown to bind the ATPase base of the 
proteasome. This was first shown for Sug1/Rpt6 and subsequently 
Sug2/Rpt4, which were first of all identified as activators of transcription 
and later as parts of the 26S proteasome (Rubin et al., 1996; Russell et al., 
1996; Swaffield et al., 1992). Further, Johnston and colleagues showed that 
ATPases of the 19S subcomplex associates with genes that are being 
transcribed (Ferdous et al., 2001; Gonzalez et al., 2002). The indications that 
the human estrogen receptor α (ER-α) is turned over at promoters in a 
periodical manner gives us further insights into this matter (Reid et al., 
2003). Chromatin immunoprecipitation (ChIP) data reveal that ER-α cycles 
on and off the promoter at a periodicity of approximately 45 minutes 
together with various transcriptional regulators including general 
transcription factors, polymerase components, coactivators and ATPases that 
cycled with a similar periodicity (Reid et al., 2003). 
Several models have been suggested to clarify the link connecting 
transcriptional activation and ubiquitin-dependent degradation. I will give 
an overview here. The “timer” model (Conaway et al., 2002; Gonzalez et 
al., 2002), assumes that monoubiquitylation of the activator is a prerequisite 
for high level gene expression and that extension of this ubiquitin into a 
K48 linked ubiquitin chain would occur subsequently. During the time 
frame between these activities, the activated activator activates transcription 
followed subsequent degradation. In the “black widow”, “kamikaze”,   27 
“suicide” or “licensing” model (Muratani & Tansey, 2003; Thomas & 
Tyers, 2000) it is also proposed that ubiquitylation is required for activation 
of transcription and that the activator has a window of time before it gets 
degraded. In this model however, it is suggested that not only the 
ubiquitylation but also the destruction of the activator is a necessary step in 
order to activate transcription. However, Kodadek and colleagues (Kodadek 
et al., 2006) suggest a “Second-generation timer model”. In this model 
monoubiquitylation and polyubiquitylation are considered as two separate 
events which might occur at different rates or even by different E3 ligases. 
Also the DUBs are suggested as a possible mechanism for inhibition of 
ubiquitin chains or even reversing the mono-ubiquitylation event. In a very 
recent report, Kodadek and colleagues extend their model by showing that 
Sug1/Rpt6 and Sug2/Rpt4 in the 19S base interact with the Gal4 activation 
domain and exercise unfolding activity on the activator. A prior 
monoubiquitylation of the activator protect it from unfolding activity and 
inactivation by the ATPases. If the activator is not monoubiquitylated, the 
ATPases will unfold the activator, disrupt the activator-promoter complex 
and inhibit transcription. They expand their model by speculating that the 
recruited 19S base ATPases transfer to the transcription complex and 
stimulate promoter release and elongation (Archer et al., 2008).  
1.5  The c-Myc transcription factor 
The proto-oncogene c-myc was first discovered as a cellular homolog of the 
oncogene of avian myelocytomatosis virus, v-myc (Sheiness & Bishop, 1979; 
Vennstrom et al., 1982). A chromosomal translocation was found in 
Burkitt’s lymphoma involving c-myc and the Ig loci, where deregulated c-
Myc expression was giving rise to constantly high levels of c-Myc (Dalla-
Favera et al., 1982). In addition to Burkitt’s lymphoma, that is a cancer of 
the B lymphocytes, Myc deregulation has been detected in a wide range of 
other human cancers and is often associated with aggressive tumours. 
Cancers include: lung, breast, cervical, ovarian, prostate and colon 
carcinoma, as well as lymphoma, melanoma and leukaemia (Dang et al., 
1999; Nesbit et al., 1999). The myc family has several members which 
include N-myc and L-myc. N-myc was discovered as homolog to v-myc that is 
amplified in neuroblastoma cell lines (Kohl et al., 1983) and L-myc was 
identified as a myc homolog that is amplified in small cell lung cancer (Nau 
et al., 1985). Myc is highly conserved during evolution and found in all 
vertebrates, as well as Drosophila (Gallant et al., 1996) and Northern sea star, 
Asterias vulgaris (Walker et al., 1992).   28 
1.5.1  Structure of c-Myc and the Myc/Max/Mad network 
The structure of the Myc protein comprises an N-terminal transactivation 
domain (TAD) and a C-terminal bHLHZip (basic helix-loop-helix leucine 
zipper) domain (Kato et al., 1990; Murre et al., 1989). Within the TAD 
there are two conserved regions named Myc homology box I and II (MBI 
and MBII). MBI and MBII were found to be necessary for Myc to 
transform rat fibroblasts together with Ras. The Myc boxes proved also to 
be essential for Myc to induce apoptosis and block differentiation (Evan et 
al., 1992; Freytag et al., 1990). MBII, but not MBI has proved to be 
necessary for transactivation and coactivator interaction (Kato et al., 1990; 
Oster et al., 2003). More recently, two additional Myc homology boxes 
have been identified: MBIII and MBIV, both necessary for cell 
transformation. MBIII seems to negatively activate pro-apoptotic activity 
(Herbst et al., 2005) whereas MBIV is needed for Myc-induced apoptosis. 
Deletion of MBIV seems to promote G2-arrest (Cowling et al., 2006). Both 
MBIII deletion and MBIV deletion respectively, have defects in activation 
and repression of several target genes even though they affect Myc 
transactivation to a much lower extent than a MBII deletion mutant 
(Cowling et al., 2006; Herbst et al., 2005). 
 
 
Myc binds DNA as a heterodimer together with its obligatory partner-
protein Max (Blackwood & Eisenman, 1991). The bHLHZip domains of 
Myc and Max dimerize and the basic region interacts with the E-box 
sequence CACGTG and similar sequences in the major groove of DNA. 
Max on the other hand can bind DNA as a homodimer (Luscher & Larsson, 
1999). Furthermore, Max can also heterodimerize with other members of 
the bHLHzip-family including Mad (Mad1, Mxi1, Mad3 and Mad4, also 
known as Mxd1-4 (Hurlin & Huang, 2006)), Mnt and Mga. Like Myc these 
proteins cannot homodimerize and bind DNA on their own, but when 
forming a heterodimer with Max they recognize and bind E-box sequences. 
Figure 4. Protein structure of Myc, Max and Mad   29 
The Mad proteins antagonize Myc and the Mad/Max complex forms a 
strong repressor of transcription. The Mad/Max heterodimer repress 
transcription, at least partly, by recruiting a co-repressor complex Sin3A and 
Sin3B that interacts with a number of proteins including histone deacetylases 
HDAC1 and HDAC2 that deacetylates histones in order to produce a more 
tightly packed chromatin structure, for a review see (Ayer, 1999). Myc is 
expressed at very low levels in resting cells and its expression is induced 
when cells begin to grow whereas Max is expressed equally in both resting 
and proliferating cells and Mad is only expressed in resting cells. Hence, the 
expression of Myc dependent genes will be repressed by Mad/Max in 
resting cells, where Mad is expressed a t  h i g h  l e v e l s  ( f o r  a  r e v i e w  s e e  
(Latchman, 1998)). Mnt, as well as the Mad proteins, possesses a Sin3 
interaction domain (SID) and also recruite HDACs in order to repress 
transcription. However, Mnt is constitutively expressed during the cell cycle 
(Hurlin et al., 1997) in contrast to the Mad proteins that forms dimers with 
Max predominantly in resting or differentiated cells (Ayer & Eisenman, 
1993). Mga (Max’s giant associated protein) is also a transcriptional repressor 
that binds E-box sequences. Mga’s biological function remains unknown, 
but it has been identified as a part of an E2F6 repression complex (Ogawa et 
al., 2002). 
1.5.2  Myc and transcription 
Myc has approximately 25.000 binding-sites in the human genome and 
potentially regulates a large portion of all human genes. The amount of Myc 
binding-sites however exceeds the number of Myc molecules in 
proliferating cells, which indicates that Myc is binding each site only 
temporarily and work with a “hit and run” mechanism (Adhikary & Eilers, 
2005). Myc activates transcription by recruiting cofactors to target gene 
promoters. These cofactors include histone acetyltransferases (HAT), 
chromatin modulating proteins, basal transcription factors, DNA methyl-
transferases, histone demethylases, E3-ligases, DUBs, AAA ATPases, 
mediator subunits, kinases and other factors (Adhikary & Eilers, 2005; Eilers 
& Eisenman, 2008). The first co-factor described was TRRAP 
(Transactivation/ transformation associated protein) which is a huge protein 
that binds Myc’s MBII in a direct manner (McMahon et al., 1998). TRRAP 
is a component of the SAGA complex (SPT/ADA/Gcn5/Acetyltansferase) 
which consists of about 20 proteins, most of them conserved from mammals 
to yeast (Grant et al., 1998; Saleh et al., 1998; Vassilev et al., 1998). Gcn5 
possess histone acetyltransferase (HAT) activity but many of the proteins 
within the SAGA complex have unknown functions. TRRAP can also   30 
interact with the H2A/H4 histone acetylase TIP60 (Ikura et al., 2000). 
Histone H4 acetylation has shown to be tightly linked to Myc 
transactivation (Frank et al., 2001). TIP48 and TIP49 ATPase domain-
containing cofactors are also found in complex with TRRAP, but 
mutational analysis have shown that they can bind Myc independently of 
TRRAP (Ikura et al., 2000; Wood et al., 2000). A mutation in TIP49 that 
disrupts the ATPase activity inhibits Myc-induced transformation, probably 
by enhancing Myc-induced apoptosis, shows that TIP49 is biologically 
important. TIP48 and TIP49 do not possess HAT activity, but they have 
been found in complexes with chromatin remodeling activity which 
displaces nucleosomes (Jonsson et al., 2004). Their structural similarity to the 
AAA ATPase chaperones (Vale, 2000) suggests that they may have a 
function in protein folding or assembly of complexes.  
 
 
 
Figure 5. Myc-Max-Mad network and some interacting coactivators. (This figure was remade 
from an original figure, printed with permission fron N. von der Lehr.) 
 
CBP (CREB-binding protein) and p300 are other HATs that interact with 
Myc and are recruited to Myc target genes in vivo. There are conflicting 
reports regarding where in the protein structure CBP and p300 bind Myc. 
One is implying the transactivation domain (Faiola et al., 2005), but others 
report that CBP and p300 interact with the C-terminal domain of Myc 
(Vervoorts et al., 2003). Further, Myc interacts with the mediator complex 
both in vitro and in vivo in a TAD dependent but MBII independent manner   31 
(Bouchard et al., 2004). Moreover, CDK9 (cyclin dependent kinase 9) and 
cyclin T1 subunits of P-TEFb (positive transcription elongation factor b) 
that phosphorylates RNA polymerase’s C-terminal tail prior to promoter 
release, have shown to interact with Myc’s extreme N terminus (Bouchard 
et al., 2004; Eberhardy & Farnham, 2002; Kanazawa et al., 2003). This is the 
same region where the mediator is believed to bind Myc (Bouchard et al., 
2004). PARP-10 is a protein possessing monoADP-ribose activity and has 
been co-purified with Myc in Jurkat T cells. Interestingly, it has been shown 
that PARP-10 overexpression inhibit Myc+Ras transformation of cells, 
however no effects on Myc transactivation has been observed (Kleine et al., 
2008; Yu et al., 2005). Further, Myc has been proposed to promote 
clearance of RNA pol II from Myc-activated targets and inhibits clearance 
from Myc-repressed target genes (Barsyte-Lovejoy et al., 2004; Bouchard et 
al., 2004; Eberhardy & Farnham, 2001; Eberhardy & Farnham, 2002). 
Moreover, E3-ligases have been implicated in Myc activated transcription. 
Ubiquitylation by Skp2 (which will be discussed in paper I and II) and 
HectH9 have proven to increase Myc’s transactivational capacity (Adhikary 
et al., 2005; Kim et al., 2003; von der Lehr et al., 2003).  
Myc has also been reported to be involved in transcriptional repression of 
p15
Ink4b and p21
Cip1. This repression is mediated by Miz-1, which recruits 
Myc-Max complexes to target promoters where they bind DNA via Miz-1 
in order to repress transcription. This Myc-Max recruitment is believed to 
block Miz-1 from binding p300 and thereby not being able to activate 
transcription (Peukert et al., 1997; Seoane et al., 2001; Staller et al., 2001; 
Wu et al., 2003). Additionally, Myc has proven to recruit DNMT3a (DNA 
methyltransferase 3a) to Myc-Miz complexes suggesting that methylation of 
DNA is a component of Myc-Miz mediated gene repression (Brenner et al., 
2005). 
1.5.3  Post-translational modifications and degradation of Myc 
The Myc protein has a half-life of 20-30 minutes and is degraded via the 
ubiquitin-proteasome pathway (Bahram et al., 2000; Flinn et al., 1998; 
Gross-Mesilaty et al., 1998; Salghetti et al., 1999). Several regions within 
Myc have proved to be important for its stability including the 
phosphorylation sites Threonine 58 (T58) and Serine 62 (S62) in MBI. T58 
is a mutational hotspot in Burkitt’s lymphoma and is frequently mutated in 
other lymphomas (Bhatia et al., 1993). The absence of T58 results in 
inefficient ubiquitination and decreased proteasome mediated turnover 
(Bahram et al., 2000). T58 has been suggested to be phosphorylated by 
glycogen synthase kinase 3 (GSK3) and S62 by extracellular receptor kinase   32 
(ERK) (Henriksson et al., 1993; Lutterbach & Hann, 1994; Pulverer et al., 
1994). The phosphorylation of T58 is dependent on a prior phosphorylation 
of S62 (Lutterbach & Hann, 1994; Sears et al., 2000). Sears and colleagues 
have reported that phosphorylation of S62 stabilizes Myc, while T58 
phosphorylation destabilizes Myc (Sears et al., 2000). This results in a model 
with a stable phospho-S62Myc intermediate, which switches to an unstable 
phospho-S62-phospho-T58Myc when GSK-3 recognizes phospho-S62Myc 
for further phosphorylation. Sears and co-workers further suggest that the 
serine/threonine phosphatase PP2A dephosphorylate S62 after a prior cis-
trans conformational change performed by Pin1 (Sears, 2004; Yeh et al., 
2004). Several E3 ligases have been identified to interact with Myc which 
will be discussed in the results and discussion chapter. 
1.5.4  Biological function of Myc 
The Myc transcription factor has been estimated to potentially regulate as 
many as 15% of the total number of genes in the human genome. Myc 
affects genes involved in cell cycle regulation, metabolism, protein 
biosynthesis, cell adhesion, angiogenesis and apoptosis (Dang et al., 2006). 
As mentioned earlier, Myc is connected to many human cancers and is 
often associated with aggressive tumours. Cotransfection of Myc and Ras 
oncogenes is sufficient to converte rat embryo fibroblasts into tumour cells 
(Land et al., 1983). Myc is also contributing to tumour formation by 
upregulating hTert that prevents telomere shortening and thereby 
promoting imortalisation of cells (Wang et al., 1998; Wu et al., 1999a). 
Further, Myc has been implicated in genetic instability. Overexpressed Myc 
induces DNA-damage and abrogates the p53 mediated DNA-damage 
response, which in turn is enabling cells with damaged genomes to enter the 
cell cycle (Felsher & Bishop, 1999; Vafa et al., 2002). 
Myc affects the cell cycle 
The Myc transcription factor is not distributed evenly throughout the cell 
cycle. Myc levels are increasing from the early G1 phase and peaking at the 
G1/S transition, for subsequent reduction to a low basic level. Myc is able to 
overcome the G1/S checkpoint and induce cells to go into S-phase. Myc 
directly regulates many genes involved in cell cycle regulation. Chromatin 
immunoprecipitation assays (ChIP) reveal that Myc is present on the 
promoters of cyclin D1 and D2, cyclin dependent kinase 4 (Cdk4) and 
cyclin B1 (Bouchard et al., 2001; Fernandez et al., 2003; Hermeking et al., 
2000; Menssen & Hermeking, 2002). Additionally, Cdk4 has been 
implicated in Myc-mediated transformation (Miliani de Marval et al., 2004).   33 
In Drosophila, cyclin A, cyclin B and Cdk4 have been identified as Myc 
target genes (Orian et al., 2003). Together with Miz1, Myc represses the 
Cdk-inhibitors p21
Cip1 and p15
Ink4b (Seoane et al., 2001; Wu et al., 2003). 
p21
Cip1 repression by Myc is responsible for the failure of Myc-transformed 
cells to arrest in G1 after DNA damage (Herold et al., 2002; Seoane et al., 
2002). The tumour suppressor p53 upregulates p21
Cip1 after exposure to 
DNA damage in normal cells. Additionally, Myc represses the Cdk-inhibitor 
p27
Kip1 directly as well as indirectly by inducing transcription of SCF
Skp2 E3 
ligase component Cks1 that is involved in ubiquitylation and degradation of 
p27
Kip1 (Keller et al., 2007). In addition, Myc represses genes involved in 
growth arrest e.g. Gadd45 (Barsyte-Lovejoy et al., 2004; Marhin et al., 
1997) and Gas1 (Lee et al., 1997). Taken together, these activities of Myc 
result in activation of the cyclin E/Cdk2 complex, which in turn 
phosphorylates the Rb protein, resulting in release of the Rb-mediated 
repression of E2F, which is transformed into an activator. E2F subsequently 
activates a large number of genes involved in cell cycle progression.  
Cell growth and metabolism 
An increased cell cycle and proliferation rate demands increased synthesis of 
proteins. The rate of protein synthesis is increased almost three-fold in Myc-
overexpressing fibroblasts in comparison to Myc knock-out cells (Mateyak 
et al., 1997). A number of ribosomal proteins have been identified as Myc 
targets to meet the need of increased protein synthesis, including Nucleolin 
and BN51 (Greasley et al., 2000). Furthermore, overexpression of Myc 
induces a Drosophila phenotype with large cell size (de la Cova et al., 2004; 
Moreno & Basler, 2004), but this could not be confirmed in mice (Trumpp 
et al., 2001). Myc has also proven to be involved in regulation of RNA 
polymerase I and RNA polymerase III (PolIII) by several groups (Arabi et 
al., 2005; Gomez-Roman et al., 2003; Grandori et al., 2005; Grewal et al., 
2005). Myc binds to the Pol III specific transcription factor TFIIIB and and 
directly activates Pol III transcription. ChIP experiments revealed that Myc 
directly binds Pol III-transcribed tRNA and 5SrRNA genes, which are 
critical for protein synthesis (Gomez-Roman et al., 2003). As mentioned 
above, Myc has also been demonstrate d  t o  b e  i n v o l v e d  i n  R N A  p o l  I  
transcription. Myc has been shown to directly stimulate rDNA transcription 
in response to mitogenic signals and thereby play a key role in regulating 
ribosome biogenesis and cell growth (Arabi et al., 2005; Grandori et al., 
2005; Grewal et al., 2005). To sum up, these observations suggest that 
overexpression of Myc induces large cell size by activating ribosome 
biogenesis.   34 
Myc is involved in several metabolic pathways. Many of the key-enzymes 
in glycolysis are regulated by Myc which is consistent with the implication 
of Myc as an enhancer of glucose uptake. Target genes in the glycolysis 
includes hexokinase II, phosphofructokinase, enolase A glucose transporter I 
(GLUT1) and lactate dehydrogenase A (LDHA) (Kim et al., 2004; Menssen 
& Hermeking, 2002; O'Connell et al., 2003; Osthus et al., 2000). LDHA has 
been suggested to be required for transformation since depletion of LDHA 
abrogates Myc induced transformation of fibroblasts. Another metabolic 
pathway where Myc plays a key role is the iron metabolism. The genes that 
encode the iron-responsive element-binding protein-2 (IRP2) and the 
transferrin receptor are induced by Myc and the H-ferritin and NRAMP1 
are repressed by Myc (Bowen et al., 2002; O'Connell et al., 2003; Wu et al., 
1999b). This results in an increase of the iron pool available in the cytosol. 
Further, Myc regulates nucleotide metabolism. This is accomplished by 
inducing ornithine decarboxylase (ODC) and carbamoyl phosphate 
synthase-aspartate transcarbamylase-dihydroorotase (CAD) which are 
essential for nucleotide synthesis (Bello-Fernandez et al., 1993; Miltenberger 
et al., 1995). 
Myc in apoptosis 
Myc was found to be a potent inducer of apoptosis in the beginning of the 
nineties, which at the time seemed somewhat surprising for an oncogene, 
but was suggested to be a build-in safety mechanism to defend the cell 
against inappropriate proliferation (Askew et al., 1991; Evan et al., 1992). 
Curiously, Myc-induced apoptosis requires the same regions of Myc as 
transactivation and transformation do (Evan et al., 1992). Shortly after Myc 
had proven to be involved in programmed cell death, the oncoprotein E2F1 
and the viral oncogene E1A also showed involvement in apoptosis 
indicating a general role for oncoproteins in apoptosis (Kowalik et al., 1995; 
Mymryk et al., 1994; Qin et al., 1994; Rao et al., 1992; Wu & Levine, 
1994). Further, Bcl-2 is an oncoprotein that inhibits apoptosis and proved to 
cooperate with Myc (Vaux et al., 1988). The Eµ-bcl-2/myc mice, 
overexpressing Myc and Bcl-2, show hyperproliferation of B cells and 
develop tumours much faster than Eµ-myc mice, that solely overexpress 
Myc (Strasser et al., 1990). In cell cultures Bcl-2 showed to abrogate Myc-
driven apoptosis in a manner that did not affect Myc’s proliferative activities 
(Bissonnette et al., 1992; Fanidi et al., 1992; Wagner et al., 1993).  
Myc has shown to induce apoptosis in both a p53-dependent and a p53-
independent manner. The p53-dependent pathway is well established and 
involves Myc activating ARF that inhibits Mdm2 and thereby stabilizing   35 
p53 which leads to either growth arrest or apoptosis (for a review see 
(Meyer et al., 2006)). Cytochrome c release from the mitochondrial 
membrane, which is a requirement for formation of the apoptosome and 
subsequent caspase activation, has shown to be triggered by Myc in several 
studies (Juin et al., 1999). The pro-apoptotic protein Bax of the Bcl-2 
family, has shown to functionally cooperate with Myc (Juin et al., 2002). 
Bax also mediates apoptosis triggered by Myc and inhibits Myc-induced 
lymphomagenesis (Eischen et al., 2001). Since apoptosis can be triggered by 
an activated oncogene it has to be overcome in a cancerous cell. Loss of 
proapoptotic regulators is one strategy to become resistant to programmed 
cell death. Mutations in the p53 tumour suppressor, is seen in more than 
50% of human cancers and results in the removal of the DNA damage sensor 
that can induce the apoptotic effector cascade (Harris, 1996). 
1.6  The von Hippel-Lindau (VHL) tumour supressor 
The VHL tumour suppressor gene was mapped to the short arm of 
chromosome 3 (3p25-26) in 1988 (Seizinger et al., 1988) and a few years 
thereafter the gene was cloned (Latif et al., 1993). The VHL gene is widely 
expressed in most tissues (Richards et al., 1996) even tough tumours of von 
Hippel-Lindau disease are predominantly seen in the central nervous system 
(CNS), kidneys, adrenal glands, retina, pancreas, endolymphatic sac and 
reproductive organs. von Hippel-Lindau disease is a hereditary cancer 
syndrome that occurs roughly 1 in 36.000 child births (Maher et al., 1991; 
Neumann & Wiestler, 1991). VHL disease was described in the literature as 
early as in 1894 by Treacher Collins, but it got its name from discoveries 
made a decade later by Eugene von Hippel and Arvid Lindau.  
1.6.1  The VHL protein and its interaction-partners 
The VHL locus encodes a single mRNA that gives rise to two protein 
products: pVHL30 and pVHL19, due to an internal initiation of translation 
(Iliopoulos et al., 1998). pVHL19 starts at amino acid 54 of pVHL30. The 
first “53 amino acid-polypeptide” consists of eight acidic pentameric amino 
acid repeats and has an unknown function. Very few tumour-associated 
mutations are found in this region, indicating that both the VHL19 and 
VHL30 gene products are required to be dysfunctional for tumours to arise 
(Barry & Krek, 2004). No functional distinction is known between pVHL30 
and pVHL19 but they localized to different subcellular compartments. 
pVHL19 is predominantly found in the nucleus and pVHL30, is shuttling 
between the cytoplasm and nucleus (Duan et al., 1995). There are also   36 
indications that pVHL30 can associate with the microtubule network 
(Hergovich et al., 2003). Moreover, VHL has proven to be essential during 
embryonal development. Homozygous vhl 
-/- embryos die between E10,5 
and E12,5 due to lack of vasculogenesis of the placenta (Gnarra et al., 1997).  
As described above, VHL possess E3 ligase activity and targets hypoxia 
inducible factor  (HIF) for oxygen dependent degradation. HIF 
comprises HIF1α, HIF2α and HIF3α,  with the function of HIF3 being 
poorly understood (Gordan & Simon, 2007). HIF1 is widely expressed in 
many cell types whereas HIF2 is mainly expressed in endothelial cells, 
kidney, heart, lung, small intestine and liver (Gordan & Simon, 2007; 
Rankin et al., 2007). The HIFs consists of a constitutively expressed β 
subunit (ARNT) and an oxygen-dependent α subunit. In aerobic conditions 
the α-subunit, HIFα, gets hydroxylated by prolylhydroxylases (PHD1-3) and 
recognized by VHL for ubiquitylation and subsequent proteasomal 
degradation. During limited oxygen conditions, which is often the case in 
tumours, the PHDs cannot hydroxylate HIFα and the subsequent 
recognition by VHL is therefore abolished. HIFα accumulates in the cell and 
dimerise with HIFβ at hypoxia responsive elements (HRE) on target 
promoters in order to induce hypoxia inducible genes. p300/CBP is 
recruited to the promoter and a hypoxia response to adapt the cell to low 
oxygen conditions is turned on. The target genes differ somewhat between 
HIF1 and HIF2. HIF1 regulates glycolytic enzymes (Hu et al., 2003) 
whereas HIF2 preferentially regulates EPO (Rankin et al., 2007), OCT4 
(Covello et al., 2006), cyclin D1 and TGFα (Raval et al., 2005). It should be 
noted that HIF2 regulates cyclin D1 only in RCC (renal cell carcinoma) 
cells (Bindra et al., 2002). VEGF (vascular endothelial growth factor) and 
ADRP (adipose differentiation-related protein) are examples of common 
targets for HIF1 and HIF2. 
HIF and Myc 
During hypoxic conditions, glycolysis replaces oxidative phosphorylation 
and the cell cycle is slowed down by induction of cyclin dependent kinase 
(cdk) inhibitors (Dang et al., 2008). The cdk inhibitors p21 and p27 have 
been reported to be induced by HIF-1 (Carmeliet et al., 1998; Goda et al., 
2003). During the last few years, there have been several reports showing 
functional interaction between HIF and Myc.  
Huang and co-workers suggest that HIF-1α induces cell cycle arrest by 
functionally counteracting Myc which is achieved by displacing Myc-
binding from the p21
cip1 promoter (Koshiji et al., 2004). They further suggest 
that this also is the case for the Myc-activated genes: MSH2, MSH6 and   37 
Nbs1, which are involved in DNA-repair, where HIF displaces Myc from 
the transcription factor Sp1 in the Myc target promoter (Huang, 2008; 
Koshiji et al., 2005; To et al., 2006).  
HIF2 promotes cell-cycle progression in hypoxic cells. This correlates 
with enhanced c-Myc promoter binding, transcriptional effects on both 
activated and repressed target genes, and interactions with Sp1, Miz1 and 
Max (Gordan et al., 2007a). HIF-1 contributes to the regulation of growth 
factor-stimulated glucose metabolism even in the absence of hypoxia (Lum 
et al., 2007). Both Myc and HIF-1 induce basically all glycolytic enzymes, 
but additionally Myc promotes mitochondrial biogenesis in order to 
produce biosynthetic substrates (for a review see (Gordan et al., 2007b). 
Semenza and colleagues suggest that HIF1 activates the Myc repressor 
Mxi, and that HIF1 promotes proteasome dependent degradation of Myc 
independent of Mxi (Zhang et al., 2007). The Semenza and Dang labs 
further show that HIF1 and dysregulated Myc cooperate to promote 
glycolysis by inducing hexokinase2 and pyruvate dehydrogenase 1 (PDK1) 
as well as VEGF by using a Burkitt’s lymphoma model system with 
inducible Myc (Kim et al., 2007). They also suggest that HIF1 is needed for 
Myc-mediated tumourigenesis (Gao et al., 2007).  
1.6.2  Clinical manifestations of von Hippel-Lindau disease 
Before thorough screening of VHL-patients became routine, mean survival 
age was below 50 years of age. The main cause of death was renal cell 
carcinoma and heamangioblastoma (Maher et al., 1990; Neumann et al., 
1992). The VHL disease can be classified into two subgroups depending on 
the presence or absence of pheochromocytoma. Type 1 patients are 
subjected to a low risk of pheochromocytoma, but can develop all other 
tumours associated with the disease, whereas type 2 patients are exposed to a 
high risk of pheochromocytoma. Type 2 families are further subdivided into 
three groups: 2A, 2B and 2C. Type 2A patients have a low risk of renal cell 
carcinoma whereas type 2B patients have a high risk. Families with type 2C 
have pheochromocytoma only (Kaelin, 2002). 
As mention above, VHL tumours are mainly found in the central nervous 
system (CNS), kidneys, adrenal glands, retina, pancreas, endolymphatic sac 
and reproductive organs. Haemangioblastoma of the CNS is affecting 60-
80% of VHL patients and is the most common tumour in von Hippel-
Lindau disease (Lonser et al., 2003). Haemangioblastoma are highly 
vascularised, benign tumours in the CNS that can be a risk due to pressure 
on surrounding tissue and are a major cause of death. Haemangioblastoma 
can also affect the retina, where it can cause vision defects or blindness. The   38 
major malignant neoplasm in von Hippel Lindau disease is renal cell 
carcinoma (kidney cancer arising from the renal tubule), which is seen in 
24-45% of VHL patients (Choyke et al., 1995; Neumann et al., 1992) Renal 
lesions are often multiple (Walther et al., 1995) and commonly give rise to 
metastasis. Metastatic RCC has a very poor prognosis with a mean survival 
of less then one year (Barry & Krek, 2004). Pheochromocytoma is a 
neuroendocrine tumor of the adrenal glands which secretes excessive 
amounts of catecholamines. It arises in 10-20% of VHL patients and is rarely 
malignant (Walther et al., 1999). Pancreatic involvement is seen in most 
patients with VHL disease. Although pancreatic cysts are most common, 8-
17% of patients with VHL disease develop tumours in pancreas which can 
be malignant (Hammel et al., 2000).  
1.6.3  Mutations in the VHL gene 
As mentioned above, VHL is a hereditary cancer syndrome and inheritance 
of a mutant VHL allele predisposes to tumour formation. VHL behaves as a 
classic Knudson two-hit tumour suppressor gene. The two-hits occur when 
heterozygous VHL carriers lose or inactivate their remaining wild type VHL 
allele by somatic mutation (second hit) (Knudson & Strong, 1972). As many 
as 20% of VHL patients have no family history of VHL disease, i.e. the first 
hit mutation occurs de novo (Glenn G, 1999; Sgambati et al., 2000).  
Some genotype-phenotype correlations have been found in von Hippel-
Lindau disease. Low risk of pheochromocytoma (type 1 VHL disease) 
individuals, almost exclusively express a truncated or misfolded VHL protein 
or harbour a mutation that lead to the complete loss of VHL protein. Type 
2 VHL disease individuals on the other hand usually carry a missense 
mutation (Chen et al., 1995; Neumann & Bender, 1998; Zbar et al., 1996). 
Taken together, this leads to the speculation that pheochromocytoma 
development reflects a VHL “gain of function”, or that pheochromocytoma 
development requires partial but not complete loss of VHL protein function 
(Kaelin, 2002). 
Known VHL mutations can be viewed in the “VHL mutation database” 
(http://www.umd.be/VHL/) (Beroud et al., 2000). 823 point-mutations are 
posted here to date. The most common are R167 (54 cases), R161 (33 
cases), V155 (24 cases) and Y98 (23 cases), whose functions are packing of 
-helices, elongin C-interaction (R161 and V155) and HIF-interaction, 
respectively.    39 
1.7  Signalling pathways 
Multicellular organisms need a communication system between cells to be 
able to coordinate their own behaviour with that of other cells for the 
benefit of the organism as a whole. The mechanism of communication is 
mainly constituted of extracellular signal molecules produced by cells to 
attend their neighbouring cells or cells further away in the organism, cell-
surface receptor proteins, which bind the signal molecule and transmit the 
signal into the cell, and intracellular signaling proteins that distribute the 
signal to appropriate part of the cell. The signaling pathways in mammalian 
cells can be broadly divided into three pathways: signaling through G-
protein linked cell-surface receptors (e.g. adenylyl cyclase (cyclic AMP)), 
signaling through enzyme-linked cell surface receptors (e.g. Ras, PI 3-
kinase, Jak-Stat) and signaling pathways that depend on regulated proteolysis 
(e.g. Wnt, Notch, Hedgehog, NF-κB) (Alberts et al., 2002). 
Of particular relevance for this thesis is the cytokine IFN- and its 
signalling pathway, which will be discussed below.  
 
1.7.1  Interferon- 
Interferons (IFN), interleukins, growth factors and tumour necrosis factors 
are members of the large cytokine family involved in cellular 
communication during cell growth and differentiation, immune response, 
embryogenesis and many other processes. IFNs respond to double-stranded 
RNA, a key feature of viral infection and are important in limiting the 
spread of certain viruses. The most wellknown interferons are , β and . 
Hematopoietic cells are the major producers of IFN- and fibroblasts are a 
major cellular source of IFN- are produced by the infected cell whereas 
IFN- is produced by T-cells and natural killer cells upon antigen 
presentation (Bach et al., 1997). The interferons are produced very early in 
infection and are counted as the first line of defence to many viruses. IFN- 
represses proliferation, practices antiviral activities and activates the 
immunesystem by inducing macrophages, class I and class II MHC, natural 
killer cells and T-cells (Roitt et al., 1998). IFN- is also possessing anti-
tumour properties for a review see (Schroder et al., 2004). 
The IFN- receptor is comprised of two ligand-binding
 IFN- receptor 1 
chains associated with two signal-transducing IFN- receptor 2
 chains and 
associated signaling machinery. IFN- mainly signals through the Jak (Janus 
kinase) - Stat (signal transducers and activators of transcription) pathway. 
There are four known Jaks (Jak1-3 and Tyk2) and seven Stats (Stat1, 2, 3, 4, 
5a, 5b and 6). For IFN-, the associated Jaks are Jak1 and Jak2 which   40 
preferently activate Stat1, but other Stats have also been implicated in IFN- 
signalling. IFN- binding causes a conformational change of the IFN- 
receptor, inducing inactive Jak2 kinase to undergo autophosphorylation and 
activation, which in turn allows Jak1 transphosphorylation by Jak2. 
Activated Jak1 then phosphorylates each IFN- receptor 1 chain to form 
two adjacent docking sites for Stat1. After binding the IFN- receptor, the 
Stats get phosphorylated and dimerise with each other. The Stat1 dimer 
enters the nucleus and binds
 to promoter elements to initiate or suppress 
transcription of
 IFN--regulated genes. For a review see (Schroder et al., 
2004). Targets genes involved in proliferation includes the G1 repressors 
Ink4 and the the G1/S repressors Cip/Kip. IFN- transcriptionally induces 
p21 (Kominsky et al., 1998; Xaus et al., 1999) and p27 (Harvat et al., 1997; 
Mandal et al., 1998; Matsuoka et al., 1999) and downregulate c-Myc (Raveh 
et al., 1996). IFN- affects Myc through several pathways, both Rb 
dependent and Rb independent as well as by increasing the levels of Mad1 
(Dey et al., 1999). In addition, IFN- has been reported to destabilize Myc-
Max complexes, which correlated with reduced phosphorylation of Myc 
(Bahram et al., 1999).   41 
2   Aims of this study 
The general objective of this study was to gain insight into the function and 
regulation of the transcription factor and oncoprotein Myc. By gaining more 
detailed knowledge about the mechanisms which regulate Myc degradation, 
we wanted to shed light on how Myc is regulated during different cellular 
conditions. Further we also wanted to investigate the importance of 
ubiquitylation for the function of Myc in cell cycle regulation and 
transactivation of target genes. Deeper understanding of Myc regulation and 
function may potentially result in new strategies and therapeutic applications 
for treatment of cancer.
2.1  Specific aims 
  To identify E3 ligases involved in ubiquitylation and degradation of 
Myc (paper I, II and III). 
  To investigate whether there are E3 ligases that exerts other or 
additional functions on Myc apart from protesomal degradation 
(paper I, II and III). 
  To elucidate the mechanism by which IFN- inhibits Myc function, 
in particular to evaluate the role of the ubiquitin/proteasome system 
(paper IV). 
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3  Results and discussion 
3.1  SCF
Skp2 promotes ubiquitylation and degradation of Myc 
(paper I and II) 
Previous studies have demonstrated that Myc is degraded by the ubiquitin-
proteasome pathway and that phosphorylation of Thr-58 plays an important 
role in this process (Bahram et al., 2000; Flinn et al., 1998; Salghetti et al., 
1999; Sears et al., 1999). Our goal was to identify an E3-ligase responsible 
for ubiquitylation of Myc and screened several E3-ligases, in particular F-
box proteins since they often bind phosphorylated substrates. We also 
checked other proteins of the SCF (Skp1-Cullin-F-box protein) complex 
for interaction with Myc. We found that the F-box protein Skp2 indeed 
interacted with Myc both in cells using reciprocal coimmunoprecipitation 
assays and by bimolecular fluorescence complementation assays, as well as in 
vitro by GST-pulldowns. By cotransfecting the SCF components Cul1, Skp1 
and Skp2 together with Myc, we also showed that the Myc-Skp2 
interaction takes place in the context of a SCF complex. Skp1 bound Myc 
only when Skp2 and Cul1 were cotransfected whereas Skp2 interacted with 
Myc independently of Skp1 and Cul1. We further mapped the interaction 
domains on Myc to the highly conserved Myc box II (MBII) and the 
HLHZip domain. Curiously, these regions are also involved in 
transcriptional regulation and cellular transformation. To address the issue of 
degradation, we measured Myc protein levels after blocking protein 
synthesis with cycloheximide (CHX) and found that when cotransfecting 
Skp2 together with Cul1, Myc half-life was drastically reduced. Also a 
dominant negative Skp2-mutant, Skp2deltaF which abolishes binding to the 
SCF-complex, could not degrade Myc. We additionally provided evidence 
for this by knocking down Skp2 expression with siRNA, which resulted in   44 
more stable Myc. These results imply that Myc is stabilised in cells with 
reduced SCF
Skp2 E3-ligase activity. Further, the MBII mutant and the 
MycdeltaC-terminal+deltaMBII mutant were more stable than Myc wt in 
CHX-chases, which is compatible with the model that SCF
Skp2 cannot target 
Myc for degradation when the Skp2 binding site is deleted. In 
ubiquitylation assays we showed that cotransfections of Myc and the 
dominant negative Skp2deltaF drastically reduced the amount of 
ubiquitylated Myc. We further showed that this effect could be abrogated by 
additionally cotransfecting Skp2wt. Taken together these results suggest that 
Skp2 binds to and promotes ubiquitylation of Myc which subsequently 
results in proteasomal degradation. However, since we have not been able to 
demonstrate ubiquitylation of Myc by SCF
Skp2 in vitro, the effect we see on 
Myc ubiquitylation could also be indirect via another E3 ligase. 
3.2  The interaction between Myc and Skp2 is cell cycle 
regulated (paper I) 
Since Skp2 is an important protein in cell cycle regulation, mainly by 
degrading p27, we wanted to test whether the Myc-Skp2 interaction was 
cell cycle regulated. For this we used peripheral blood lymphocytes (PBL) 
that were activated by PHA and interleukin-2 (IL-2). Resting PBLs reached 
S-phase 36 hours post PHA and IL-2 stimulation which was confirmed by 
FACS analysis and increased cyclin A expression. The Myc level was low in 
resting cells and increased steadily as the cells progressed through G1-phase 
with a peak at 12 hours followed by a subsequent decline to a low level 
when the cells entered S-phase. Myc-Skp2 interaction coincided with 
decreased level of Myc, increased level of Skp2 and S-phase entry. Myc 
mRNA and the rate of protein synthesis were constant during the time, 
indicating that the decreased Myc level was due to degradation. These 
results suggest that Skp2 participates in Myc turnover at the G1-S phase 
transition in the cell cycle.  
Previous reports have suggested that Myc promotes S-phase entry 
(Grandori et al., 2000). To see whether Skp2 affects Myc-induced S-phase 
entry, MycER (Myc fused to the ligand-binding domain of the estrogen 
receptor) expressing Rat1 cells were induced by 4-hydroxy-tamoxifen (4-
OHT) which causes activation of Myc and induces the cells to enter S-
phase. Surprisingly, transfection of Skp2 further enhanced the cells to enter 
S-phase whereas the Skp2deltaF-mutant reduced the ability of S-phase 
entry. This was also performed in p27
-/- cells in order to determine if the 
effect was indirect via the p27 Cdk inhibitor. Similar results were seen in the   45 
p27
-/-MEFs expressing MycER, therefore we concluded that the mechanism 
was p27 independent.  
3.3  SCF
Skp2 stimulates transcriptional activation of Myc targets 
(paper I) 
Since certain E3 ligases in yeast had been reported to also work as activators 
of transcription (Kuras et al., 2002; Salghetti et al., 2001), we wanted to test 
whether this was the case also for Skp2 in mammalian cells. We utilised a 
reporter assay system with the -prothymosin promoter, which is an 
established Myc target, fused to the luciferase (Luc) gene. Luc-activity was 
then measured as a read-out for promoter activity. We found that the 
cotransfections of Myc and Skp2 enhanced -proT promoter activity 
compared to Myc wt alone. Cotransfections with Myc and Skp2deltaF 
repressed the -proT activity indicating that transcriptional stimulation by 
Myc requires intact Skp2 E3 ligase activity. To further strengthen the 
importance of Skp2, we performed the assay in Myc
-/- cells and Skp2
-/- cells, 
respectively. The results indicated that both Myc and Skp2 were required 
for activation of the -proT promoter. Further, siRNA oligos targeting 
Skp2 reduced the activity on the -proT promoter to the same extent as 
siRNA against Myc. To make sure that the observed effects on Myc 
induced transcription by Skp2 siRNA or cotransfections of Skp2deltaF 
dominant negative mutant were not due to indirect cell cycle effects, we 
arrested the cells in G1 or S-phase by novastatin, hydroxyurea or 
aphidicholin. Neither of these cell cycle blocking agents did affect the 
activity of the -proT promoter. To determine if these activating effects on 
transactivation also applied for endogenous targets, we utilized the MycER 
system and transfected the cells with Skp2 and Skp2deltaF respectively. After 
activation of MycER we measured mRNA for the Myc-targets cyclin D2 
and ODC and found that both cyclin D2 and ODC mRNA were 
upregulated when Skp2 was transfected and downregulated by Skp2deltaF. 
In summary, both Myc and Skp2 seemed to be required for activation of the 
Myc target promoters -proT, ODC and cyclin D2. 
3.4  Skp2 as well as the proteasomal subunit Sug1 are involved 
in Myc’s transactivation (paper I and II) 
To strengthen Skp2’s role in Myc activated transcription, we investigated 
whether Skp2 was physically present together with Myc on Myc target 
promoters. For this we performed chromatin immunoprecipitation (ChIP)   46 
which revealed that Skp2 indeed is present on the cyclin D2 promoter. 
Additionally, we also found Cul1, ubiquitin as well as the proteasomal 
subunits Sug1, Rpt3, Rpn7 and 2 on the cyclin D2 promoter. Also, we 
showed that this was Myc-dependent since none of the proteins Myc, Skp2, 
Sug1 or ubiquitin, were associated with the cyclinD2 promoter in Myc
-/-
cells. Further, we showed in coimmunoprecipitations that Myc and the 
AAA ATPase subunit Sug1 which is a component of the regulatory base of 
the proteasome, interacted in transfected Cos7 cells. To further address the 
role of Sug1, we knocked down endogenous Sug1 expression with Sug1 
siRNA in cotransfections with the -proT-Luc construct. The results 
showed that siRNA knock down of Myc, Skp2 and Sug1, respectively, 
reduced the activity of the -proT promoter to a similar extent. This 
implies that the Sug1 proteasomal subunit as well as Skp2 are necessary for 
Myc transactivation of the -proT promoter.  
 Taken together, this gives us a speculative model, where Skp2 
ubiquitylates Myc at promoters, leading to subsequent recruitment of the 
base of the proteasome and the remaining lid and core proteasome 
thereafter. Alternatively, the whole proteasome could be recruited at once. 
Since we have not shown whether SCF
Skp2 ubiquitylates Myc at target gene 
promoters, there is a possibility that SCF
Skp2 ubiquitylates other proteins on 
the promoter, named protein x in the figure (paper II, fig 3), which are 
responsible for recruitment of the proteasome. After recruitment, Skp2, 
Sug1, ubiquitin and/or the proteasome exert coactivator activity, that 
potentially activates target gene transcription. Ubiquitylated Myc is then 
degraded and the promoter is cleared for another round of transcription to 
take place.  
  The nature of Skp2’s coactivator activity is presently unknown. One 
suggestion is that Skp2 ubiquitylates and degrades negative regulators of 
transcription and therefore act in a positive way on Myc’s transactivation. 
Another possible way of action is an autoregulatory loop, where Myc needs 
to be eliminated in order to complete the transcription cycle. Another 
possibility is that ubiquitylation of Myc or other proteins at the promoter has 
a non-proteolytic function and the ubiquitin-modification serves to recruit 
other proteins important for transcription. Since we have shown that the 
APIS subunit Sug1 interacts with Myc and that siRNA knocking down 
Skp2 and Sug1 respectively reduced the activity of the -proT promoter, 
one plausible guess is that the coactivator activity is mediated by the APIS 
complex. The APIS ATPases have been implicated in transcriptional 
activation in yeast through their chaperon-activity. Kodadek and colleagues 
suggest in a recent model that Sug1/Rpt6 and Sug2/Rpt4 in the APIS   47 
interact with the Gal4 activation domain and exercise unfolding activity on 
the activator. A prior monoubiquitylation of the activator would protect it 
from unfolding activity and inactivation by the ATPases. If the activator is 
not monoubiquitylated, the ATPases will unfold the activator, disrupt the 
activator-promoter complex and inhibit transcription. The authors further 
speculate that the recruited 19S base ATPases transfer to the transcription 
complex and stimulate promoter release and elongation (Archer et al., 
2008). If this model is true also for Myc and for mammalian cells, 
ubiquitylation or rather monoubiquitylation, would protect Myc from being 
unfolded, thereby maintaining Myc-driven transcription. However, further 
studies are required to reveal the role of ubiquitylation and AAA ATPase 
activity in the regulation of transcription. 
3.5  Myc is targeted by additional E3s (paper I and II) 
We show that Myc and Skp2 interact in the G1-S transition of the cell 
cycle, but Myc degradation is also substantial during other phases of the cell 
cycle for instance in early G1 when Myc and Skp2 do not seem to interact 
strongly. This together with earlier studies showing that Myc degradation 
was phosphorylation dependent made us believe that Skp2 probably was not 
the only E3 ligase involved in degradation of Myc. Further, considering the 
importance of Myc in such a variety of cellular functions it would be 
surprising if Myc was not tightly regulated on different levels and in different 
phases of the cell cycle. 
Since our Skp2-papers have been published, an additional E3-ligase has 
been identified for ubiquitylation and degradation of Myc. This E3-ligase, 
Fbw7, interacts with phosphorylated MBI within Myc’s transactivation 
domain (Welcker et al., 2004; Yada et al., 2004). Our initial hypothesis that 
an E3-ligase would interact with phosphorylated Thr-58 proved to be right, 
we just found the “wrong” E3-ligase. 
Also the HectH9 E3 ligase has shown to interact and ubiquitylate Myc. 
However, this ubiquitylation is of a different nature. HectH9 was reported 
to ubiquitylate Myc by attaching K63-linked ubiquitin chains leading to 
transcriptional activation without subsequent degradation (Adhikary et al., 
2005).  
3.6  The tumour suppressor VHL interacts with Myc (paper III) 
As mentioned above, we initiated the Skp2-study with screening E3-ligases 
for interaction with Myc. However, apart from Skp2 we found an additional   48 
E3-ligase, VHL, which is part of a CBC (Cul2-elongin C-elongin B) 
complex to interact strongly with Myc. We further confirmed this 
interaction with reciprocal coimmunoprecipitations in transfected Cos7 and 
293-T cells, endogenously in P493-6 cells, in living cells with BiFC and in 
in vitro assays. We also showed that Myc preferentially bound the pVHL19 
isoform, which is nuclear, even though Myc could bind both pVHL19
 and 
pVHL30. BiFC assays also confirmed that the interacting Myc-VHL 
complex has a nuclear localisation. We then mapped the binding region on 
Myc to the MBII and the bHLHzip domain. Interestingly, these are the 
same regions as are required for Skp2 interaction and additionally, these 
regions are also involved in transcriptional regulation and cellular 
transformation.  
We utilised VHL-deletion mutants to map the binding site on VHL and 
found that binding to Myc seemed to involve two potential binding sites. 
However, when studying VHL’s 3D-structure and adding that to the results 
from the CoIPs with Myc and VHL deletion mutants we could narrow 
down the binding region by educated guesses. Our proposed binding region 
is a dual binding site comprising the amino acids 91-113 as well as 195-204 
located in the β-domain of VHL. As mentioned above, these regions are just 
hypothetical and there could also be other explanations, for instance that 
there could be an inhibitory domain in the VHL114-154 region, since a 
VHLdelta114-154 mutant interacted strongly with Myc, hypothesising that 
something that interferes with Myc–VHL interaction binds there. We also 
wanted to test VHL point mutants commonly found in VHL disease for 
interaction with Myc. Neither the Y98N mutant, which has been reported 
not to bind HIF-1, nor the C162F mutant, which has been reported to not 
interact with elongin C and the CBC complex, showed any reduction in 
binding to Myc. Neither did the tumour mutants S65 nor S111, remarkably 
though the S65 mutant did show stronger interaction with Myc than VHL 
wt.  
An interesting task for the future will be to establish if any mutational hot 
spots are responsible for interaction with Myc and whether this correlates 
with any particular type of von Hippel Lindau disease. For this purpose we 
have utilised the “VHL mutations database” (http://www.umd.be/VHL/) 
to connect the most common mutations with the literature regarding 
genotype-phenotype correlations. We plan to clone the most common 
mutations from each disease type (von Hippel Lindau disease type 1, 2A, 2B 
and 2C) and investigate their properties with respect to interaction with 
Myc.   49 
 
Table 1. Mutants involved in von Hippel Lindau disease.  
Mutant aa
1  Hits on UMD
2 Disease  type  Reference 
E52K 1(1)  1  (Olschwang,  1999) 
E55E 1(5)  1  (Olschwang,  1999) 
R64P 1(4)  2C  (Hoffman et al., 2001) 
S65W 4(13)  1  (Chen et al., 1995) 
S65L 4(13)  1  (Olschwang,  1999) 
E70L 1(5)  1  (Olschwang,  1999) 
76delF 9(20)  1  (Zbar et al., 1996) 
76delFinsC 6(20)  1  (Crossey et al., 1994; Maher et al., 1996) 
S80Q 0(8)  2C  (Zbar et al., 1996) 
S80N 2(8)  1  (Olschwang,  1999) 
S80R 1(8)  1  (Olschwang,  1999) 
P81S 17(19)  1  (Brauch et al., 1999; Zbar et al., 1996) 
R82P 2(6)  2B  (Gnarra et al., 1994; Olschwang, 1999) 
V84L 1(1)  2C  (Hoffman et al., 2001) 
P86S 5(19)  2B (Olschwang,  1999) 
P86A 1(19) 1  (Zbar et al., 1996) 
P86L 8(19) 1  (Zbar et al., 1996) 
P86R 1(19) 1  (Corn et al., 2003; Stolle et al., 1998) 
W88S 4(12)  1  (Olschwang,  1999) 
Y98H 21(23)  2A  (Corn et al., 2003; Hsu et al., 2006) 
Y98N  1(23)  2B  (Liu & Nussinov, 2008) 
G104G 1(4)  1  (Olschwang,  1999) 
T105P 3(3)  1  (Olschwang,  1999) 
S111R 2(9)  1  (Corn et al., 2003) 
S111N 4(9)  1  (Zbar et al., 1996) 
Y112H  3(6)  2A  (Barry & Krek, 2004; Rathmell et al., 
2004) 
Y112N  1(6)  2B  (Barry & Krek, 2004) 
Y112stop 2(6)  1  (Zbar et al., 1996) 
G114 0(20) 1  (Zbar et al., 1996) 
H115Q 2(9)  1  (Olschwang,  1999) 
W117C 6(12)  1  (Olschwang,  1999) 
L118P 4(6)  1  (Olschwang,  1999) 
delta 114-154    1  (Corn et al., 2003; Hsu et al., 2006) 
F119S 1(6)  2C  (Hoffman et al., 2001) 
F119L  5(6)  2B  (Barry & Krek, 2004)   50 
Mutant aa
1  Hits on UMD
2 Disease  type  Reference 
V130L 6(8)  1  (Olschwang,  1999) 
N131K 1(3)  2A  (Olschwang,  1999) 
F136S 4(11)  1  (Olschwang,  1999) 
P154P 1(4)  2A  (Olschwang,  1999) 
P154L 2(4)  2A/2B  (Corn et al., 2003; Hsu et al., 2006) 
V155 1(24) 1?  (Japan,  1995) 
Y156D 1(6)  2B  (Olschwang,  1999) 
Y156C 1(6)  1  (Olschwang,  1999) 
T157I 5(8)  2A  (Olschwang,  1999) 
L158P 7(18)  1  (Gnarra et al., 1994) 
R161G 3(33)  2B?  (Zbar et al., 1996) 
R161stop 18(33)  1/2  (Stolle et al., 1998; Zbar et al., 1996) 
R161P 1(33)  1/2  (Zbar et al., 1996) 
R161Q  7(33)  2A  (Olschwang, 1999; Stolle et al., 1998; 
Zbar et al., 1996) 
C162R 6(17)  1  (Zbar et al., 1996) 
C162Y 3(17)  1  (Zbar et al., 1996) 
C162F 2(17)  1  (Hoffman et al., 2001; Stolle et al., 1998) 
C162W 4(17)  1/2B  (Olschwang,  1999) 
V166F 4(8)  2A  (Olschwang,  1999) 
R167W  24(54)  1/2A/2B  (Olschwang, 1999; Stolle et al., 1998; 
Zbar et al., 1996) 
R167Q  28(54)  1/2B/2  (Olschwang, 1999; Rathmell et al., 2004; 
Stolle et al., 1998; Zbar et al., 1996) 
V170G 2(10)  1  (Olschwang,  1999) 
L188P 1(10)  1  (Olschwang,  1999) 
L188V 5(10)  2C  (Hoffman et al., 2001; Hsu et al., 2006; 
Stolle et al., 1998) 
L188Q 1(10)  1  (Chen et al., 1995) 
Q195 ter  2(2)  2B  (Crossey et al., 1994) 
R200W 3(3)  Chuvash 
Polycythemia 
(Rathmell et al., 2004) 
1Mutant aa refers to the mutated amino acid. 
2Hits on UMD refers to the number of reports on “VHL 
mutations database” (Beroud et al., 2000) http://www.umd.be/VHL/. The numbers are written in 
the format: # reports for this exact aa exchange (# reports for this aa position). 
3.7  The Myc-VHL interaction is HIF independent (paper III) 
Since VHL binds HIF in an oxygen dependent manner, we wanted to test 
whether the Myc-VHL binding was affected by oxygen conditions. In   51 
CoIPs, we showed that Myc and VHL could interact during hypoxia and 
further, after 20 hours of hypoxia the Myc-VHL binding had somewhat 
increased whereas Myc levels seemed to be reduced, implying that hypoxia 
lower the steady state level of Myc, but increase the Myc-VHL binding.  
Even though the VHL-Y98N mutant with diminished binding to HIF-1 
(Tanimoto et al., 2000) still interacted with Myc we wanted to establish 
whether Myc and HIF could compete for binding to VHL. By using a 
polypeptide comprising a part of the oxygen dependent domain (ODD) of 
HIF-1 in increasing concentrations we could not abolish the Myc-VHL 
nor the Myc1-215-VHL interaction. However, when high concentrations 
of the polypeptide was transfected, the total level of Myc and Myc1-215 
respectively were reduced, suggesting that released HIF-1 might regulate 
the steady state levels of Myc protein or mRNA. 
3.8  VHL plays a role in ubiquitylation of Myc but seems not to 
be involved in proteasomal degradation (paper III) 
Since VHL is an E3 ligase, we wanted to test if VHL was involved in 
ubiquitylation of Myc. Ubiquitin-assays showed that VHL did not seem to 
affect Myc ubiquitylation, but the VHL-Y98N and VHL-C162F mutants 
strongly repressed ubiquitylated Myc. This suggests that the VHL mutants 
work in a dominant negative fashion and that VHL directly or indirectly 
regulates ubiquitylation of Myc.  
We next raised the question whether the potential ubiquitylation of Myc 
was followed by degradation in the same manner as when Myc is 
ubiquitylated by the E3 ligases Skp2 and Fbw7. In a panel of cell lines with 
functional and dysfunctional/absent VHL respectively, we observed that 
Myc steady state levels were higher in those cells with dysfunctional or 
absent VHL. This made us believe that VHL was involved in degradation of 
Myc and we tested this hypothesis by 
35S pulse-chases and cycloheximide 
block of translation. Surprisingly, chase data revealed that absence or 
presence of functional VHL did not seem to affect the turnover rate of Myc 
in the cell lines used. However, we the increased protein levels of c-Myc in 
cells lacking functional VHL correlated with increased c-myc mRNA 
expression, indicating that the VHL status of the cell affects Myc expression 
pre-translationally.   52 
3.9  VHL is associated with some Myc target promoters and is 
suggested to activate transcription of Myc target genes 
(paper III) 
Since VHL affected ubiquitylation of Myc without obvious effect on Myc 
turnover, we wanted to test whether VHL had a function in Myc 
transactivation. We utilized the reporter assay system with an -prothymosin 
promoter-Luc construct as described above and found that VHL had little 
effect on Myc induced transcription. However, when cotransfecting the 
VHL-Y98N and VHL-C162F (data not shown) mutants with Myc we 
noticed repression of Luc-activity already at low concentrations of the 
mutants. This suggests that the VHL-Y98N and VHL-C162F mutants work 
in a dominant negative fashion in the same manner as in the ubiquitylation 
assay. This would imply a possible regulatory role for VHL in Myc induced 
transcription. To strengthen the evidence for VHL’s role in transcription, 
we performed chromatin immunoprecipitation (ChIP) assays, where DNA-
protein interaction was measured. We confirmed that VHL was physically 
present on the CAD and cyclin D2 Myc target promoters, but not on the 
ODC promoter. This suggests a model where VHL is involved in 
transcription of some Myc targets, but not with a general mechanism 
including all Myc targets.  
3.10 Hypothetical model of regulation of Myc by VHL (paper III) 
Taking all this data together, we suggest a hypothetical and speculative 
model (figure 6). In this model we propose that VHL binds Myc-Max 
complexes on target gene promoters. There VHL ubiquitylates Myc which 
possibly enhances activation of Myc target genes. This ubiquitylation by 
VHL does not seem to induce turnover of Myc under the conditions we 
have used. We cannot exclude however, that VHL not have an effect on 
Myc degradation in a different cellular context, such as hypoxia. 
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Figure 6. Hypothetical model of VHL-Myc interplay. VHL interacts with Myc on Myc target 
promoters which leads to ubiquitylation of Myc but without subsequent degradation. VHL, 
ubiquitylated Myc and/or other factors present, induces activation of Myc targets. 
Whether HIF is involved in this regulation is not entirely clear. HIF and 
Myc do not seem to bind VHL on the same site although possibly in the 
same region, the β-domain. Neither did HIF seem to compete with Myc for 
binding which fits with the idea that they not bind exactly the same residues 
on VHL. Further, the Myc-VHL interaction is not oxygen-dependent, 
actually Myc and VHL seemed to interact even stronger during hypoxia, 
which correlated with reduced Myc protein levels. It has been reported that 
Myc is downregulated during hypoxia (Corn et al., 2005; Zhang et al., 
2007). It will therefore be an important task for the future to elucidate 
whether Myc is downregulated during hypoxia in a VHL dependent 
manner.  
3.11 IFN- induces degradation of Myc in a Ser-62-dependent 
manner (paper IV) 
Previous research in the group had revealed that IFN- destabilises Myc-
Max complexes which correlated with reduced overall Myc phosphorylation 
(Bahram et al., 1999). We now wanted to further investigate the 
mechanisms by which IFN- inhibits Myc function. We utilised the U-937 
differentiation model where Thr-58 mutated v-Myc inhibits TPA-induced 
differentiation of U-937 monocytes. In this model system, IFN- abrogates 
the v-Myc effects and restores differentiation and G1-arrest (Oberg et al., 
1991). We could now show that IFN- treatment increases the degradation 
of both v-Myc and c-Myc in U-937-Myc6 cells as well as in several other   54 
cell lines including Colo320 colon carcinoma cells with amplified c-Myc, 
2fTGH fibrosarcoma cells but not in the 2fTGH fibrosarcoma sublines U3A 
and U3B which lack STAT1 and JAK1, respectively. This indicates a 
requirement for STAT1 and JAK1 in IFN- induced degradation of Myc. 
Further we showed that IFN- enhances the amount of ubiquitylated Myc 
and that a proteasome inhibitor rescues Myc from degradation when treated 
with IFN-.  
Phosphorylation of Thr-58 requires a prior phosphorylation of Ser-62, 
which has been suggested to be targeted by Erk and unknown Cdks. 
Phosphorylated Ser-62 has also been suggested to stabilize Myc (Sears et al., 
2000). We showed that IFN- reduced v-Myc Ser-62 phosphorylation and 
increased degradation of the Myc-T58A mutant but not of the Myc-S62A 
mutant. Taken together this implies that IFN- decreases phosphorylation of 
Myc Ser-62 and that IFN- induced Myc degradation is Ser-62 dependent. 
3.12 Cdk2 phosporylates Myc at Ser-62 (paper IV) 
We next asked whether the reduced Myc Ser-62 phosphorylation was due 
to inhibition of a kinase or activation of a phosphatase or both. To address 
this question we transfected U2OS cells with the Myc-T58A mutant in 
order to make sure that Ser-62 would be the only targeted phosphorylation 
site and then treated these cells with a panel of kinase inhibitors. We found 
that the Cdk1/Cdk2 inhibitor roscovitine, was the most potent agent in 
reducing Ser-62 phosphorylation. Since kenpaullone which prominently 
inhibits Cdk1 had less effect we concluded that Cdk2 is the kinase that 
phosphorylates Myc Ser-62. We further proved this in vitro by using GST-
Myc and recombinant cyclin/Cdk2 complexes and showed that Myc was a 
substrate for cyclinE/Cdk2 and to a lesser extent for cyclinA/Cdk2. Also, 
we arrested U-937 cells in early S-phase and found that Myc Ser-62 was 
phosphorylated in these cells. This effect could be abrogated by roscovitine, 
suggesting that Cdk2 is the major Myc Ser-62 kinase in early S-phase. 
Moreover, roscovitine increased the turnover rate of both c-Myc and v-
Myc in U937-Myc6 cells, further strengthening the role for Cdk2 in Myc 
degradation. 
3.13 IFN- represses Cdk2 by upregulation of p27 (paper IV) 
To confirm that IFN- represses Cdk2 activity, we performed in vitro kinase 
assays which showed that Cdk2 activity was strongly repressed within four 
hours of IFN- exposure. In addition this correlated with reduced   55 
phosphorylation of Rb which is also a Cdk2 target. To find the missing link 
between IFN- and Cdk2 activity, we tested expression of the Cdk2 
inhibitors p21 and p27, which have been reported to be upregulated by 
IFN- (Harvat et al., 1997; Kominsky et al., 1998; Mandal et al., 1998; 
Matsuoka et al., 1999; Xaus et al., 1999). Indeed, p27 protein levels were 
upregulated by IFN- treatment which correlated with increased p27-Cdk2 
complex formation, reduced Myc Ser-62 phosphorylation and increased 
Myc degradation. p21 expression also increased, but only transiently. We 
excluded the possibility that the effects of IFN- were due to indirect effects 
of the cell cycle by measuring the cell cycle distribution after IFN-+TPA 
or roscovitine treatments. No G1 accumulation at the essential time points 
was observed. Further, to rule out the possibility of upregulation of 
phosphatase action by IFN-, we measured PP2A activity after IFN- 
treatment and found no changes in PP2A activity. 
  To further analyze the role of p27, we coexpressed p27 and Myc and 
found that p27 reduced the levels of Myc wt as well as the Myc-T58A 
mutant, but not the Myc-T58A/S62A double mutant. Additionally, IFN-
treatment did not affect Myc steady state level in p27-/-MEF cells. 
3.14 A novel E3 ligase is involved in p27 induced Myc 
degradation (paper IV) 
Since the SCF
Fbw7 E3 ligase previously had been shown to ubiquitylate and 
degrade Myc via MBI in a phospho-Thr-58-dependent manner (Welcker et 
al., 2004; Yada et al., 2004), we wanted to test whether Fbw7 was involved 
in p27 induced Myc turnover. However, p27 expression induced Myc 
degradation also in Fbw7/cdc4 
-/- HCT116 cells, which is in agreement with 
the ability of p27 to induce degradation of Myc-T58A. The SCF
Skp2 E3 
ligase did not seem to participate in p27 induced Myc turnover either, 
which was expected, since Skp2 does not operate via MBI (see paper I). 
Hence, a novel E3 ligase is involved in p27 induced Myc degradation. 
3.15 Cyclin E/Cdk2 and p27 are present on the cyclin D2 
promoter and are involved in Myc transactivation (paper IV) 
To further clarify the cyclinE/Cdk2-p27-Myc interactions, we performed 
coimmunoprecipitations in IFN- treated U-937 cells. We showed that Myc 
coimmunoprecipitated with both p27 and cyclin E antibodies, although the 
interactions were weaker than the Myc-Max binding indicating a transient 
interaction. In addition, the interactions of these proteins were detected on   56 
chromatin by quantitative chromatin immunoprecipitations (Q-ChIP) on 
the cyclin D2 promoter. Cyclin E and p27 were further re-ChIPed, 
protein/DNA complexes immunoprecipitated with Myc antibody were 
released and IPed over again with Cdk2 and p27 antibodies. The results 
confirmed a direct interaction. IFN- treatment decreased the amount of 
total and phosphorylated Myc as well as Cdk2, but increased the amount of 
p27 on the cyclinD2 promoter. Together these data implicate a model 
where IFN--induced p27 is transiently recruited and inhibits Myc-bound 
cyclin E/Cdk2 which results in reduced Myc phosphorylation and 
degradation of Myc via the ubiquitin/proteasome pathway.  
 Since Myc, cyclin E/Cdk2 and p27 are detected on the cyclin D2 
promoter, we wanted to evaluate whether cyclin E/Cdk2 is involved in 
Myc transactivation. In reporter-assays where the Myc-driven m4mintk-Luc 
construct was cotransfected with Myc and cyclin E/Cdk2, we showed that 
cyclin E/Cdk2 substantially enhanced Myc-driven transcription and that this 
was abrogated in IFN- treated cells. This was also confirmed by the Myc-
target  -prothymosin-Luc cotransfections with Myc and cyclin E/Cdk2. 
Additionally, this correlated with mRNA levels for the Myc-activated 
targets hTERT and ODC as well as the Myc-repressed target p21 measured 
by RT-qPCR. IFN- treatment decreased the hTERT and ODC mRNA 
levels as well as substantially induced p21 expression. 
  There are several possible ways how cyclin E/Cdk2 could activate Myc 
dependent transcription. Firstly, by acting as a coactivator implicating that 
phosphorylating Myc Ser-62 or other substrates are sufficient for activating 
transcription. It has been reported that the coactivator CBP which is 
recruited by Myc is activated by cyclin E/Cdk2. Secondly, the Cdk2 kinase 
activity may phosphorylate components of the Pol II complex or finally 
cyclin E/Cdk2 might serve as an adaptor for recruitment of other 
components that activate transcription.  
3.16 Proposed model for the IFN- induced p27/cyclin E/Cdk2/ 
Myc interplay (paper IV) 
To sum up, our data implicates a model for the IFN- induced p27-cyclin 
E/Cdk2-Myc interplay. At first, cyclin E/Cdk2 is recruited to Myc-Max 
complexes located at E-box sequences in target promoters. Secondly, cyclin 
E/Cdk2 phosphorylates Myc at Ser-62 which results in a more stable Myc-
Max complex and increased transcription of Myc target genes. In absence of 
IFN-, GSK3 recognises phosphorylated Myc Ser-62 which is a prerequisite 
for the subsequent GSK3-mediated Thr-58 phosphorylation. Further, for   57 
efficient ubiquitylation by Fbw7, the Ser-62 phosphorylation needs to be 
removed which is mediated by PP2A assisted by Pin1 (Yeh et al., 2004). In 
the presence of IFN- however, p27 is induced and recruited to the 
Myc/cyclin E/Cdk2 complex where it represses the kinase activity of Cdk2. 
Cdk2 cannot phosphorylate Myc Ser-62 and unphosphorylated Myc is 
transcriptionally less active. Also, unphosphorylated Myc is less stable than 
Ser-62 phosphorylated Myc which results in ubiquitylation and degradation 
by a presently unknown E3 ligase.   58   59 
4  Conclusions 
  SCF
Skp2 interacts with Myc and participates in Myc ubiquitylation 
and degradation by the proteasome. 
  Skp2 is a cofactor for Myc function in cell cycle regulation and 
transcriptional regulation. 
  Sug1 interacts with Myc, is physically associated with the cyclin D2 
promoter and is involved in Myc induced transcription. 
  VHL interacts with Myc and plays a role in Myc ubiquitylation and 
regulation of transcription by Myc. 
  Cyclin E/Cdk2 regulates the stability of Myc by phosphorylating 
Ser-62 and functions as a Myc cofactor. 
  IFN- induces p27 expression, which in turn inhibits cyclin 
E/Cdk2 phosphorylation of Myc Ser-62, resulting in increased Myc 
turnover via the ubiquitin/proteasome pathway. 
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